Female reproductive organ cancer
MONDO:0001416A primary or metastatic malignant neoplasm involving the female reproductive system. Representative examples include endometrial carcinoma, cervical carcinoma, ovarian carcinoma, uterine corpus leiomyosarcoma, adenosarcoma, malignant mixed mesodermal (mullerian) tumor, and gestational choriocarcinoma.
Also known as: cancer of female reproductive organ, female reproductive cancer, female reproductive organ cancer, gynecologic cancer, malignant female reproductive organ neoplasm, malignant female reproductive system neoplasm, malignant female reproductive system tumor, malignant female reproductive system tumour
4802 clinical trials for this condition and its sub-types, 245 tagged with Female reproductive organ cancer itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Female reproductive organ cancer
-
Uterine cancer 96 trials · 1,264 incl. sub-types
7 sub-types
- Cervical cancer 576 trials · 700 incl. sub-types Sub-types →
- Endometrial cancer 458 trials · 650 incl. sub-types Sub-types →
- Uterine carcinoma 3 trials · 614 incl. sub-types Sub-types →
- Uterine corpus cancer 33 trials · 85 incl. sub-types Sub-types →
- Uterine carcinosarcoma 23 trials · 32 incl. sub-types Sub-types →
- Placenta cancer 0 trials · 1 incl. sub-types Sub-types →
- Uterine adnexa cancer 0 trials Sub-types →
-
Ovarian cancer 1,004 trials · 1,200 incl. sub-types
11 sub-types
- Malignant epithelial tumor of ovary 8 trials · 656 incl. sub-types Sub-types →
- Malignant non-epithelial tumor of ovary 1 trial · 9 incl. sub-types Sub-types →
- Familial ovarian cancer 1 trial · 8 incl. sub-types Sub-types →
- Ovarian neuroendocrine neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Ovarian sarcoma 0 trials · 2 incl. sub-types Sub-types →
- Malignant ovarian cyst 1 trial
- Ovarian Wilms tumor 0 trials
- Ovarian adenosarcoma 0 trials
- Ovarian endometrioid adenocarcinofibroma 0 trials
- Ovarian lymphoma 0 trials
- Ovarian malignant mesothelioma 0 trials
-
Fallopian tube cancer 298 trials · 408 incl. sub-types
4 sub-types
- Fallopian tube carcinoma 126 trials · 182 incl. sub-types Sub-types →
- Cancer of isthmus of fallopian tube 0 trials
- Fallopian tube adenosarcoma 0 trials
- Fallopian tube leiomyosarcoma 0 trials
-
Endometrioid adenocarcinoma 13 trials · 146 incl. sub-types
6 sub-types
- Ovarian endometrioid adenocarcinoma 78 trials Sub-types →
- Endometrial endometrioid adenocarcinoma 56 trials Sub-types →
- Fallopian tube endometrioid adenocarcinoma 30 trials
- Stage I endometrioid carcinoma 16 trials
- Stage II endometrioid carcinoma 2 trials
- Cervical endometrioid adenocarcinoma 0 trials Sub-types →
-
Vulva cancer 88 trials · 102 incl. sub-types
8 sub-types
- Vulvar carcinoma 24 trials · 45 incl. sub-types Sub-types →
- Vulvar melanoma 3 trials
- Clitoris cancer 0 trials Sub-types →
- Labia minora cancer 0 trials Sub-types →
- Labium majus cancer 0 trials Sub-types →
- Mixed germ cell tumor of vulva 0 trials
- Paraurethral gland cancer 0 trials Sub-types →
- Vulva sarcoma 0 trials Sub-types →
-
Vaginal cancer 53 trials · 60 incl. sub-types
5 sub-types
- Vaginal carcinoma 12 trials · 22 incl. sub-types Sub-types →
- Malignant vaginal mixed epithelial and mesenchymal neoplasm 0 trials Sub-types →
- Vagina sarcoma 0 trials Sub-types →
- Vaginal adenosarcoma 0 trials
- Vaginal germ cell malignant tumor 0 trials Sub-types →
-
Adenosarcoma 0 trials · 2 incl. sub-types
5 sub-types
- Cervical adenosarcoma 1 trial Sub-types →
- Uterine corpus adenosarcoma 1 trial
- Fallopian tube adenosarcoma 0 trials
- Ovarian adenosarcoma 0 trials
- Vaginal adenosarcoma 0 trials
-
Gestational choriocarcinoma 0 trials · 1 incl. sub-types
4 sub-types
- Placental choriocarcinoma 1 trial
- Fallopian tube gestational choriocarcinoma 0 trials
- Gestational ovarian choriocarcinoma 0 trials
- Uterine corpus choriocarcinoma 0 trials
-
Adenocarcinofibroma 0 trials
3 sub-types
- Ovarian endometrioid adenocarcinofibroma 0 trials
- Ovarian mucinous adenocarcinofibroma 0 trials
- Uterine corpus adenocarcinofibroma 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 2103 trials in this tab.
-
Off-the-Shelf immune cells target solid tumors
Cure Recruiting nowResearchers are testing a new cell therapy called CAR001 in adults with solid tumors that have come back or stopped responding to standard treatment. CAR001 uses donor gamma-delta T cells engineered with a chimeric antigen receptor to recognize and attack cancer cells. The trial …
Phase 1/2 • Sponsor: Ever Supreme Bio Technology Co., Ltd. • Aim: Cure
Last updated Sep 11, 2026 00:00 UTC
-
Can hormone pills replace chemo for aggressive endometrial cancer?
Disease control Recruiting nowResearchers are testing whether radiotherapy followed by oral progestin tablets works as well as radiotherapy plus chemotherapy for people with high-risk endometrial cancer that lacks specific molecular markers. The trial enrolls about 600 participants and randomly assigns them t…
Phase 3 • Sponsor: University College, London • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
New hope for advanced cancers: experimental drug ACR-2316 enters first human trial
Disease control Recruiting nowThis early-stage trial tests an experimental drug called ACR-2316 in 100 people with advanced solid tumors that have spread or come back. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. It is for patients who have had up to 3 pr…
Phase 1/2 • Sponsor: Acrivon Therapeutics • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
New pill takes on advanced cancers: early trial begins
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called CSCJC3456 in 102 people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any signs that the drug can shrink tumors. Participants take the table…
Phase 1 • Sponsor: Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd. • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
New drug shows promise for Hard-to-Treat uterine and cervical cancers
Disease control Recruiting nowThis study tests a new drug called ivonescimab in 50 people with advanced endometrial or cervical cancer that has worsened after standard chemotherapy. The drug targets two proteins (PD1 and VEGF) to help the immune system fight cancer and block tumor blood supply. Researchers wi…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
New hope for advanced cancer: APR-1051 enters first human trial
Disease control Recruiting nowThis early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…
Phase 1 • Sponsor: Aprea Therapeutics • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
New drug BL-B01D1 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…
Phase 1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
Texts vs. manuals: new trial aims to help rural cancer survivors kick the habit
Disease control Recruiting nowThis study tests whether text-based support can help rural cancer survivors who smoke to quit. Participants will either receive text messages that gradually reduce cigarette use or a self-help manual. The goal is to see which approach works better for long-term smoking cessation.
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
New vaccine aims to halt ovarian cancer recurrence detected in blood
Disease control Recruiting nowThis phase II trial tests whether an IGFBP-2 vaccine, given after one dose of carboplatin, can stop ovarian cancer from growing in patients whose recurrence is detected only through a blood test. The vaccine helps the immune system target cancer cells, while carboplatin primes th…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
Targeted therapy boost for aggressive uterine cancer under study
Disease control Recruiting nowThis phase 3 trial tests whether adding targeted drugs (trastuzumab and pertuzumab) to standard chemotherapy can better shrink tumors in people with HER2-positive endometrial cancer. The study plans to enroll 360 participants with various stages of the disease. However, the trial…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
New drug combo aims to shrink HER2-Positive tumors
Disease control Recruiting nowThis study tests whether adding palbociclib to neratinib works better than neratinib alone for people with HER2-positive solid tumors (excluding breast cancer). Both drugs block signals that help cancer cells grow. The trial enrolls 70 adults with advanced or recurrent gynecologi…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
Immunotherapy duo shows promise for Tough-to-Treat uterine cancer
Disease control Recruiting nowThis phase II trial is testing whether combining two immunotherapy drugs, nivolumab and ipilimumab, works better than nivolumab alone for women with recurrent endometrial cancer that has a specific DNA repair defect (dMMR). About 81 participants will receive either the combinatio…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
Can a new drug rally the immune system against Hard-to-Treat cancers?
Disease control Recruiting nowThis early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
New app-based trial aims to shrink waistlines in endometrial cancer survivors
Disease control Recruiting nowThis study tests whether a 24-week digital wellness platform, combined with one-on-one online sessions with a dietitian, exercise pro, and therapist, can help endometrial cancer survivors lose inches around their waist and improve their health. About 148 survivors who are overwei…
Sponsor: University of Alberta • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
Experimental biologic AWT020 put to the test in Hard-to-Treat cancers
Disease control Recruiting nowResearchers are testing an experimental biologic called AWT020 in adults with advanced solid tumors that have worsened after at least one standard treatment. The phase 1 trial gives AWT020 every three weeks at increasing dose levels to find the highest dose people can tolerate an…
Phase 1 • Sponsor: Anwita Biosciences • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug HMPL-A580 enters human trials
Disease control Recruiting nowThis early-phase trial tests an experimental drug called HMPL-A580 in 186 adults with advanced or metastatic solid tumors that cannot be removed by surgery. The study aims to find a safe dose and check for early signs that the drug shrinks tumors. It is currently recruiting parti…
Phase 1/2 • Sponsor: Hutchmed • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill NP-101 tested in patients with Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Pha…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Poop pills? stool transplants may ease immunotherapy side effects
Disease control Recruiting nowThis early-stage trial tests whether a stool transplant (FMT) can help cancer patients who develop severe diarrhea or colon inflammation from immune-checkpoint inhibitor drugs. About 40 patients with various cancers will receive the transplant via colonoscopy. The main goal is to…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New antibody combo shows promise in early cancer trial
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…
Phase 1/2 • Sponsor: BioInvent International AB • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug cocktail aims to outsmart advanced cancers
Disease control Recruiting nowThis early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New bispecific antibody D3L-002 enters first human trial for Hard-to-Treat cancers
Disease control Recruiting nowThis Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…
Phase 1 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug DS3610a enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…
Phase 1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cancer drug YL217 enters first human tests
Disease control Recruiting nowThis early-phase study is testing an experimental drug called YL217 in 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and look for early signs that the drug can shrink tumors. Participa…
Phase 1 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug targets Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…
Phase 1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…
Phase 1/2 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug combo aims to keep ovarian cancer at bay
Disease control Recruiting nowThis Phase 3 trial tests whether a targeted therapy called sacituzumab tirumotecan (Sac-TMT), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer without their cancer growing. About 900 participants who have finished initial chemotherapy will…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New Triple-Drug attack on cervical cancer enters final testing
Disease control Recruiting nowThis phase 3 trial tests whether adding the experimental drug sacituzumab tirumotecan (sac-TMT) to standard immunotherapy (pembrolizumab) and a targeted therapy (bevacizumab) helps people with metastatic cervical cancer live longer. About 1,000 participants whose cancer has sprea…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug cocktail targets Virus-Linked cancers in early trial
Disease control Recruiting nowThis phase 1 study tests a combination of two drugs, pomalidomide (a pill) and nivolumab (an infusion), in adults with cancers caused by viruses like Epstein-Barr, HPV, or hepatitis. The goal is to find a safe dose and see if the drugs can shrink tumors. Up to 58 people with Kapo…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in large trial
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…
Phase 2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
First-in-Human trial asks whether HG381 is safe and tolerable in advanced solid tumors
Disease control Recruiting nowResearchers are running a first-in-human Phase 1 trial of HG381, an experimental drug given by intravenous injection, in adults with advanced solid tumors that have worsened after available treatments. The study aims to find out how safe and tolerable the drug is, how the body pr…
Phase 1 • Sponsor: HitGen Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for endometrial cancer: targeted drug BNT323 faces chemo in phase 3 trial
Disease control Recruiting nowThis Phase 3 trial tests whether the drug BNT323 (trastuzumab pamirtecan) works better than standard chemotherapy for people with recurrent endometrial cancer that expresses HER2. About 480 participants will be split into two groups based on their HER2 levels. The study measures …
Phase 3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New cancer drug GI-108 enters human trials for advanced tumors
Disease control Recruiting nowThis study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …
Phase 1/2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo therapy takes on advanced cancers
Disease control Recruiting nowThis early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…
Phase 1/2 • Sponsor: Hefei Xinzhu Biological Technology Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug aims to control advanced cervical cancer
Disease control Recruiting nowThis phase 2 trial tests a drug called lorigerlimab (MGD019) in 47 people with advanced cervical cancer that has spread or come back. The goal is to see if the drug can help control the cancer and improve survival. Participants receive the drug through an IV. The study is current…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing a new radioactive drug that seeks out a protein called Nectin-4 found on many cancer cells. The drug delivers a dose of radiation directly to the tumor, aiming to destroy it while sparing healthy tissue. About 150 adults with advanced bladder, br…
Phase 1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis early-stage study tests a new treatment for people with ovarian cancer that has come back. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack a protein (FSHR) found on cancer cells. The main goal is to check the safety of these…
Phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for womb cancer: drug duo aims to slow tumor growth
Disease control Recruiting nowThis study tests whether adding sacituzumab tirumotecan (Sac-TMT) to pembrolizumab helps people with advanced or recurrent endometrial cancer live longer without the cancer getting worse. About 1,100 participants with a specific type of endometrial cancer (pMMR) will receive eith…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug cocktail aims to fight Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…
Phase 1/2 • Sponsor: Wigen Biomedicine Technology (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Experimental injection SHR-7787 put to the test against advanced solid tumors
Disease control Recruiting nowResearchers are testing an experimental injection called SHR-7787 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial aims to find a safe dose, measure how the body processes the drug, and look for early signs that it shrinks tumors. P…
Phase 1/2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a smart drug missile take down a tough ovarian cancer?
Disease control Recruiting nowThis phase 2 trial is testing whether a targeted antibody-drug conjugate called sacituzumab tirumotecan, given alone or together with the immunotherapy pembrolizumab, can shrink tumors in people with ovarian clear cell carcinoma that has returned after prior immunotherapy. The st…
Phase 2 • Sponsor: Tufts Medical Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Shorter, personalized radiation may target endometrial cancer with fewer side effects
Disease control Recruiting nowResearchers are testing a shorter, adapted form of radiation therapy for people with high-risk endometrial cancer after surgery. The trial enrolls 20 patients and uses daily imaging to adjust the radiation plan to each person's anatomy. Participants receive moderately hypofractio…
Sponsor: Xiaorong Hou • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a pill shrink Hard-to-Treat ovarian tumors?
Disease control Recruiting nowResearchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…
Phase 1/2 • Sponsor: Heronova Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: drug targets MTAP deletion
Disease control Recruiting nowThis phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a pill turn on genes that stop cancer? new trial begins
Disease control Recruiting nowThis early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New targeted drug shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers in early human trial
Disease control Recruiting nowThis study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…
Phase 1 • Sponsor: Accent Therapeutics • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill targets tough cancers with genetic flaw
Disease control Recruiting nowThis study tests an experimental oral drug, GSK5460025, alone or with other cancer drugs, in adults whose solid tumors have specific genetic changes (dMMR or MSI-H). The goal is to see if the drug can shrink tumors and to check its safety. About 47 people with advanced cancers th…
Phase 1/2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers: early trial recruits 554 patients
Disease control Recruiting nowThis study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…
Phase 1/2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can inhaled manganese make ovarian cancer immunotherapy hit harder?
Disease control Recruiting nowResearchers are testing whether adding inhaled manganese chloride to standard chemotherapy and an anti-PD-1 immunotherapy can help people with advanced ovarian cancer that has worsened after at least two prior treatments. The trial enrolls about 120 participants and randomly assi…
Phase 3 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can an immunotherapy boost give advanced cervical cancer patients more time?
Disease control Recruiting nowResearchers are testing whether adding an experimental immunotherapy drug called GLS-010 to standard platinum-based chemotherapy, with or without bevacizumab, helps women with persistent, recurrent, or metastatic cervical cancer live longer. The trial enrolls about 424 women aged…
Phase 3 • Sponsor: Guangzhou Gloria Biosciences Co., Ltd. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
DNA-Guided immunotherapy trial aims to match drug to tumor
Disease control Recruiting nowThis study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis…
Phase 2 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Engineered immune cells take on Platinum-Resistant ovarian cancer
Disease control Recruiting nowThis early-stage trial is testing a new treatment called GB-5267 for people with ovarian cancer that no longer responds to platinum-based chemotherapy. GB-5267 is a type of immune cell therapy (CAR T cell) that has been engineered to better target cancer cells and includes an ext…
Phase 1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Could your own tumor cells fight cancer? new trial tests immune cell therapy
Disease control Recruiting nowThis phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo aims to stall endometrial cancer in High-Risk patients
Disease control Recruiting nowThis study tests whether two drugs, abemaciclib and letrozole, can help keep advanced or recurrent endometrial cancer from getting worse. About 32 people with a specific type of estrogen-sensitive cancer will take these pills daily after initial treatment. The goal is to see if t…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill shows promise in early trial for tough cancers
Disease control Recruiting nowThis early-stage trial is testing a new oral drug called ISM6331 in 100 adults with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug can shrink tumors. Partic…
Phase 1/2 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a smart drug deliver a toxic payload directly to cancer cells?
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…
Phase 1 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New gene therapy combo aims to boost ovarian cancer survival
Disease control Recruiting nowThis phase 3 trial tests whether adding a gene therapy called IMNN-001 (given into the abdomen) to standard chemotherapy helps people with advanced ovarian, fallopian tube, or peritoneal cancer live longer. About 500 newly diagnosed patients will be randomly assigned to receive e…
Phase 3 • Sponsor: Imunon • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill takes on brain tumors and metastases in early trial
Disease control Recruiting nowThis study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…
Phase 1/2 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Could a natural pill prevent blood clots in ovarian cancer patients?
Disease control Recruiting nowThis study tests whether a daily pill called isoquercetin, made from a plant compound, can reduce blood markers linked to clot risk in people with ovarian cancer. About 90 participants receiving chemotherapy will take either isoquercetin or a placebo for up to 6 weeks. The goal i…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can steroids help cancer patients resume a promising therapy?
Disease control Recruiting nowThis study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Cancer patients on targeted therapy get extended safety monitoring
Disease control Recruiting nowThis study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for hard-to-treat ovarian cancer: experimental drug targets key protein
Disease control Recruiting nowThis study tests a new drug called INCB123667 in 160 people with a type of ovarian cancer that no longer responds to platinum chemotherapy and has high levels of a protein called cyclin E1. The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants…
Phase 2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for cancer patients with autoimmune conditions: immune checkpoint inhibitor trial expands access
Disease control Recruiting nowThis study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Hope for Platinum-Resistant ovarian cancer: new pill takes on chemo
Disease control Recruiting nowThis Phase 3 trial tests a new oral drug, INCB123667, against standard chemotherapy in 466 people with platinum-resistant ovarian cancer that overexpresses cyclin E1. The goal is to see if the new drug can delay cancer growth or improve survival. Participants will be randomly ass…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cancer drug DXP-106 enters early human testing
Disease control Recruiting nowThis early-stage trial tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if DXP-106 works better when given alone or with chemotherapy. Participants receive the drug by…
Phase 1 • Sponsor: Singlomics Biopharmaceuticals Zhuhai Co., Ltd. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cancer drug QLC5508 enters first human safety tests
Disease control Recruiting nowThis early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…
Phase 1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Could less be more? new trial tailors endometrial cancer treatment to tumor type
Disease control Recruiting nowThis phase II study is testing whether women with certain types of early-stage endometrial cancer can safely receive less aggressive treatment after surgery. The approach is guided by the tumor's molecular profile—either POLE-mutated or p53 wildtype/NSMP. Around 393 participants …
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill targets rare cancer mutation in early trial
Disease control Recruiting nowThis study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…
Phase 1/2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Immunotherapy before Chemo-Radiation shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing whether the immunotherapy drug dostarlimab (TSR-042), followed by standard chemoradiation and surgery, can effectively treat advanced mismatch repair deficient (dMMR) solid tumors. About 212 adults with locally advanced dMMR cancers will receive the drug int…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug combo aims to wipe out hidden ovarian cancer cells
Disease control Recruiting nowThis study tests whether adding the experimental drug IMNN-001 to standard chemotherapy and bevacizumab can better eliminate remaining cancer in people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. About 30 participants will be randomly assi…
Phase 1/2 • Sponsor: Imunon • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cell therapy trial hopes to tackle tough cancers
Disease control Recruiting nowThis early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…
Phase 1/2 • Sponsor: Second Life Therapeutics • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cancer drug BI 3810944 enters first human tests
Disease control Recruiting nowThis early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug EVOLVE104 takes on tough cancers in early human trial
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…
Phase 1 • Sponsor: EvolveImmune United, Inc • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cancer drug ART6043 enters human trials for advanced tumors
Disease control Recruiting nowThis study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the m…
Phase 1/2 • Sponsor: Artios Pharma Ltd • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill targets HER2 cancers in phase 2 trial
Disease control Recruiting nowThis study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for Platinum-Resistant ovarian cancer: experimental drug ubamatamab enters phase 2 trials
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called ubamatamab, alone or combined with other cancer drugs, in 220 people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The study aims to see how…
Phase 2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Less invasive surgery may improve recovery for ovarian cancer patients
Disease control Recruiting nowThis study compares two surgical approaches for people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have received chemotherapy before surgery. One group will have minimally invasive surgery (small incisions), and the other will have standard open surger…
Phase 3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: first human trial of BGB-58067 begins
Disease control Recruiting nowThis early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for rare cancers: drug combo trial launches
Disease control Recruiting nowThis study tests a combination of two drugs, nilotinib (a pill) and paclitaxel (given by IV), for people with rare advanced cancers that have not responded to standard treatments. The goal is to see if the drugs can shrink or stop tumor growth. About 82 adults with specific rare …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…
Phase 1/2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Could a simple mask help cancer patients avoid a breathing tube?
Disease control Recruiting nowThis study tests whether a non-invasive ventilation mask (NIPPV) can reduce the need for intubation in cancer patients with respiratory failure. Researchers will compare NIPPV plus standard oxygen therapy to standard oxygen therapy alone in 256 participants. The goal is to see if…
Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New cancer drug targets two proteins at once in early trial
Disease control Recruiting nowThis early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New smart drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called TUB-040 for people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate, meaning it delivers a powerful chemotherapy directly to cancer cell…
Phase 1/2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug BG-C477 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a radioactive 'Smart Bomb' target tough tumors?
Disease control Recruiting nowResearchers are testing an experimental radioactive drug called 177Lu-FAP-VG11 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to seek out and attach to a protein called FAP, which is found on many tumor cells. This early …
Early phase 1 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for recurrent ovarian cancer: targeted drug combo enters human trials
Disease control Recruiting nowThis study tests a new drug called SHR-A1811 combined with standard chemotherapy (carboplatin and bevacizumab) in 150 women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to find the safest dose and see if the combination shrinks tumors …
Phase 1/2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can an experimental pill slow advanced solid tumors? a phase 1 trial puts HW221043 to the test.
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…
Phase 1 • Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New Antibody-Drug combo takes aim at Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis study tests a new drug called raludotatug deruxtecan (R-DXd) in people whose high-grade serous ovarian, peritoneal, or fallopian tube cancer has returned after platinum chemotherapy. R-DXd is an antibody-drug conjugate that seeks out cancer cells and delivers a toxic payload…
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Experimental biologic M1-c6v1 put to the test in Hard-to-Treat solid tumors
Disease control Recruiting nowResearchers are testing an experimental intravenous biologic called M1-c6v1 in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The Phase I trial gives escalating doses to a small group of participants to check safety, find th…
Phase 1 • Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New Triple-Action antibody takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New antibody drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New immunotherapy combo shows promise for tough cancers
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called volrustomig, either alone or with chemotherapy, in people with advanced cervical, head and neck, esophageal, or mesothelioma cancers. The study aims to see if the drug can shrink tumors and how safe it is. About 257 partic…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New antibody combo aims to fight back against recurrent ovarian cancer
Disease control Recruiting nowThis study is testing a new drug called ubamatamab, given alone or with another drug called cemiplimab, in people with ovarian cancer or other cancers that have come back after treatment. The main goals are to check safety, find the right dose, and see if the drugs can shrink tum…
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for Hard-to-Treat breast cancer: targeted drug trial begins
Disease control Recruiting nowThis early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Could a Weight-Loss drug slow endometrial cancer growth?
Disease control Recruiting nowThis study tests whether tirzepatide, a drug used for weight loss and diabetes, can slow tumor growth in people with obesity-driven endometrial cancer. About 20 participants will take the drug before their scheduled hysterectomy. Researchers will compare cancer cell activity in t…
Early phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New 'seek and destroy' therapy for metastatic cancer enters human testing
Disease control Recruiting nowThis early-stage study tests a two-part system to find and treat metastatic cancer. First, a radioactive tracer is used to spot tumors on a PET scan. Then, a similar radioactive drug is given to deliver radiation directly to the cancer cells. The goal is to see if this approach i…
Phase 1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combo aims to outsmart resistant ovarian cancer
Disease control Recruiting nowThis early-phase trial is testing whether combining two targeted drugs—abemaciclib and olaparib—can help women with ovarian cancer that has stopped responding to platinum-based chemotherapy. The study will enroll 42 participants to find the safest dose and check for side effects.…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug MK-8294 tested in patients with advanced cancers
Disease control Recruiting nowThis early-phase study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety, see if people can tolerate it, and find the highest safe dose. About 67 participants will receive the drug, and…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combo targets tough ovarian cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called DT2216 combined with the chemotherapy paclitaxel in people whose ovarian cancer has returned and is resistant to platinum-based treatments. The main goal is to find the highest safe dose of DT2216 when given with paclitaxel. About 30…
Phase 1 • Sponsor: Elizabeth Stover, MD, PhD • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug SKB118 aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…
Phase 1/2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combo shows promise in early cancer trial
Disease control Recruiting nowThis study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New biologic drug GEN1106 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …
Phase 1 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Experimental biological therapy VRT106 put to the test in advanced solid tumors
Disease control Recruiting nowResearchers are running a Phase I trial of VRT106, an experimental biological therapy given by intravenous drip, in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The trial enrolls about 12 people aged 18 to 75. It aims to f…
Phase 1 • Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New cancer drug KK2269 enters first human tests
Disease control Recruiting nowThis early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…
Phase 1 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug BL-M07D1 targets multiple HER2 cancers in early trial
Disease control Recruiting nowThis Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…
Phase 1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug FORX-428 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …
Phase 1 • Sponsor: FoRx Therapeutics AG • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis early-phase trial is testing a new treatment called B7-H3 CAR T cells for adults with ovarian cancer that has come back and no longer responds to platinum chemotherapy. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize an…
Phase 1 • Sponsor: Stanford University • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug combo aims to shrink advanced cervical tumors
Disease control Recruiting nowThis study tests whether combining two drugs, pembrolizumab and lenvatinib, can shrink tumors in people with advanced cervical cancer that has stopped responding to initial treatment. The trial enrolls 35 adults whose cancer has spread or cannot be removed by surgery. The goal is…
Phase 2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for advanced cancer? early trial tests MK-3120
Disease control Recruiting nowThis study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Hormone blockers and letrozole tested to spare uterus in early endometrial cancer
Disease control Recruiting nowResearchers are testing a combination of a gonadotropin-releasing hormone agonist injection and the drug letrozole in obese women with early-stage endometrial cancer that has not responded to progestin. The goal is to see if this hormone-blocking approach can shrink tumors and al…
Phase 2/3 • Sponsor: Xiaojun Chen • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug CR-001 enters human trials
Disease control Recruiting nowThis study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.
Phase 1/2 • Sponsor: Crescent Biopharma, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug SHR-4610 tested in patients with Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…
Phase 1/2 • Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Hormone combo tested as Fertility-Sparing option for early uterine cancer
Disease control Recruiting nowResearchers test whether a combination of GnRHa and letrozole can shrink early endometrial cancer or atypical hyperplasia in non-obese patients who have not responded to progestin therapy. The trial compares this regimen with Diane-35 plus metformin. About 80 participants receive…
Phase 2/3 • Sponsor: Xiaojun Chen • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for rare, deadly gynecologic cancers: drug combo trial launches
Disease control Recruiting nowThis clinical trial is testing whether a combination of two drugs—dostarlimab (an immunotherapy) and niraparib (a PARP inhibitor)—works better than standard chemotherapy for women with a rare and aggressive type of uterine or ovarian cancer called carcinosarcoma. The study will e…
Phase 2/3 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Personalized mRNA vaccine aims to train immune system against ovarian cancer
Disease control Recruiting nowThis trial tests a personalized mRNA vaccine called NeoOVIV in people with stage II or III ovarian cancer who have had surgery. The vaccine is designed to teach the immune system to recognize and attack cancer cells. Participants receive the vaccine alongside standard chemotherap…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo aims to extend remission in ovarian cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding the experimental drug Rina-S to standard care (bevacizumab or monitoring) can help keep platinum-sensitive ovarian cancer from returning after chemotherapy. About 528 participants will receive either Rina-S alone, Rina-S plus bevacizumab, b…
Phase 3 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New smart drug targets tough cancers in first human trial
Disease control Recruiting nowThis early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…
Phase 1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo aims to shrink ovarian tumors before surgery
Disease control Recruiting nowThis study tests whether giving the targeted drug mirvetuximab soravtansine together with standard chemotherapy (carboplatin) before surgery can shrink advanced ovarian, fallopian tube, or peritoneal cancers that have a specific protein (FRα). About 140 adults with stage III or I…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New combo therapy aims to shrink advanced tumors
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a new pill shrink Hard-to-Treat tumors?
Disease control Recruiting nowThis trial is testing an experimental drug called SA53-OS in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking a protein called MDM2, which may help slow or stop tumor growth. The study has two parts: first,…
Phase 1/2 • Sponsor: Lamassu Bio Inc • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for recurrent endometrial cancer: Rina-S faces off against standard chemo
Disease control Recruiting nowThis study compares a new drug called Rina-S to standard chemotherapy (paclitaxel or doxorubicin) in people with endometrial cancer that has returned or worsened after platinum-based chemo and immunotherapy. About 660 participants will be randomly assigned to receive either Rina-…
Phase 3 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New antibody GEN1079 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…
Phase 1 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug SGT003 put to the test against Hard-to-Treat solid tumors
Disease control Recruiting nowResearchers are running a phase I/IIa trial of SGT003, an experimental intravenous drug, in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look fo…
Phase 1/2 • Sponsor: Beijing Sungen Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New targeted drug enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis phase 1 trial is testing a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called tissue factor found on many cancer cells. The main goals are to…
Phase 1 • Sponsor: Adcendo ApS • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New cancer drug AGX101 enters human trials for advanced tumors
Disease control Recruiting nowThis early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…
Phase 1 • Sponsor: Angiex, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New radioactive drug targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug, 225Ac-ETN029, in 116 adults with advanced DLL3-positive cancers like small cell lung cancer or neuroendocrine tumors. The main goal is to check safety and find the right dose, while also seeing if the drug can shrink tumors. Pa…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug GEN1119 aims to fight solid tumors that resist standard care
Disease control Recruiting nowThis trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…
Phase 1 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
BioNTech launches first human test of BNT317 against advanced cancers
Disease control Recruiting nowThis early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if …
Phase 1/2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for Platinum-Resistant ovarian cancer: Rina-S trial launches
Disease control Recruiting nowThis phase 3 trial compares a new drug called Rina-S to standard chemotherapy in 82 people with platinum-resistant ovarian cancer. Participants are randomly assigned to receive either Rina-S or one of four approved chemotherapies. The goal is to see if Rina-S can delay cancer gro…
Phase 3 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New antibody M0324 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …
Phase 1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a custom mRNA vaccine keep ovarian cancer from coming back?
Disease control Recruiting nowThis early-phase trial is testing whether a personalized mRNA vaccine called NeoOVSV, given alongside standard chemotherapy and an immunotherapy drug, can safely help prevent ovarian cancer from returning after surgery. The vaccine is designed to train the immune system to recogn…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New targeted drug shows promise for Hard-to-Treat breast cancers
Disease control Recruiting nowThis early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New cancer drug FID-022 enters first human trial
Disease control Recruiting nowThis early-phase trial tests a new drug called FID-022 in 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. The drug contains two active components, including irinotecan, which is …
Phase 1 • Sponsor: Fulgent Pharma LLC. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a Two-Drug combo reawaken the immune system against resistant cancers?
Disease control Recruiting nowThis trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …
Phase 1/2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New antibody drug aims to turn immune cells against cancer
Disease control Recruiting nowThis early-stage study tests a new drug called NPX372 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the body's immune cells recognize and attack cancer cells. The main goals are to check the drug's safety and fin…
Phase 1 • Sponsor: NextPoint Therapeutics, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis early-phase trial tests a combination of two drugs—DS-8201a and olaparib—in people with advanced HER2-expressing cancers that have spread or cannot be removed. DS-8201a delivers chemotherapy directly to HER2-positive tumor cells, while olaparib blocks DNA repair in cancer ce…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New antibody drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called ONC-783 in 20 people with advanced solid tumors, including colorectal, ovarian, pancreatic, or breast cancer. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goal is to find a safe d…
Phase 1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Experimental pill GS-1206 takes aim at Hard-to-Treat solid tumors
Disease control Recruiting nowThis study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…
Phase 1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for ovarian cancer: phase 3 trial tests targeted drug against Tough-to-Treat tumors
Disease control Recruiting nowThis large Phase 3 study tests a new medicine called Sofetabart Mipitecan for people with ovarian, fallopian tube, or peritoneal cancer. It includes two groups: those whose cancer stopped responding to platinum chemotherapy within six months (platinum-resistant), and those whose …
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for advanced cervical cancer: adding immunotherapy before standard care
Disease control Recruiting nowThis phase III trial tests whether giving an extra round of chemotherapy and immunotherapy (pembrolizumab) before the usual chemoradiation can help people with high-risk, locally advanced cervical cancer live longer without the cancer growing. About 336 participants will be rando…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called AZD4956, alone or with other cancer drugs, in people with advanced or spreading solid tumors that have a specific DNA repair defect (HRR deficiency). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. …
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New radioactive drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new radioactive drug, 177Lu-INN805, in 10 people with advanced solid tumors (like head & neck, lung, breast, or sarcoma) that haven't responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers wi…
Early phase 1 • Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New radioactive drug targets FAP-Positive tumors in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New antibody drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…
Phase 1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New radiation drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a new pill shrink advanced solid tumors?
Disease control Recruiting nowThis trial tests an experimental drug called ODM-216 in adults with advanced solid tumors, which are cancers that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second checks how well that dose fights the cancer. Researc…
Phase 1/2 • Sponsor: Orion Corporation, Orion Pharma • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for tough cancers: experimental drug IMGS-001 enters human trials
Disease control Recruiting nowThis early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…
Phase 1 • Sponsor: ImmunoGenesis • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for tough endometrial cancer: Four-Drug combo trial launches
Disease control Recruiting nowThis Phase III trial tests whether adding the drug bevacizumab to a standard chemotherapy plus immunotherapy regimen can help people with a specific type of advanced or recurrent endometrial cancer (pMMR, TP53 mutated). About 255 participants will be randomly assigned to one of t…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New cell therapy targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-stage study tests a new treatment called ZI-MA4-1, made from specially engineered immune cells, in people with advanced ovarian, lung, sarcoma, or head and neck cancers that have not responded to other therapies. The treatment aims to help the body's immune system atta…
Phase 1 • Sponsor: Zelluna Immunotherapy AS • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a new drug shrink tumors that resist other treatments?
Disease control Recruiting nowThis trial tests an experimental drug called FH-006 in 150 people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if FH-006 is safe, tolerable, and can shrink tumors. Researchers will measure how the drug moves through the body and …
Phase 1/2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers with brain spread
Disease control Recruiting nowThis early-phase study tests a daily oral drug called CGT4255 in 100 adults with advanced solid tumors that have ERBB2 genetic changes or HER2 overexpression. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors, including in the brain. The …
Phase 1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New pill CT7439 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called CT7439, taken as a capsule, in about 50 people with solid tumors that have spread or cannot be removed. The study will first test CT7439 alone, then in combination with other cancer treatments. The main goals are to ch…
Phase 1/2 • Sponsor: Carrick Therapeutics Limited • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat ovarian and endometrial cancers
Disease control Recruiting nowThis early-phase trial is testing the safety and best dose of two drugs, M1774 and ZEN-3694, given together to patients with recurrent ovarian or endometrial cancer. The drugs work by blocking enzymes that cancer cells need to grow. The study aims to find a dose that is safe and …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Belzutifan extension trial aims to extend lives in VHL and advanced cancer
Disease control Recruiting nowThis extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug SKB565 aims to fight advanced solid tumors
Disease control Recruiting nowThis study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…
Phase 1/2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New pill targets HER2 cancers in promising trial
Disease control Recruiting nowThis Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…
Phase 2 • Sponsor: Bayer • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug IDP-001 takes on advanced cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…
Phase 1/2 • Sponsor: InduPro, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug VBC101 targets tough cancers in early trial
Disease control Recruiting nowThis early-stage trial tests a new drug called VBC101 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to attach to two cancer-related targets (EGFR and cMET) and deliver a toxic payload directly to cancer cells. The s…
Phase 1/2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for tough cancers: experimental drug IPN01203 enters human trials
Disease control Recruiting nowThis study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…
Phase 1/2 • Sponsor: Ipsen • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug cocktail aims to outsmart aggressive uterine cancer
Disease control Recruiting nowThis phase 3 trial is testing whether a targeted drug (trastuzumab deruxtecan) combined with immunotherapy (rilvegostomig or pembrolizumab) works better than standard chemotherapy plus pembrolizumab for people with advanced or recurrent endometrial cancer that has a specific prot…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New pill targets rare cancer gene in 30-Patient trial
Disease control Recruiting nowThis phase 2 trial tests an oral drug called lirafugratinib in 30 adults with advanced solid tumors (excluding bile duct cancer) that have an FGFR2 gene fusion or rearrangement. Participants take the drug regularly and visit the clinic for checkups. The main goal is to see if the…
Phase 2 • Sponsor: Elevar Therapeutics • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new drug tackle Hard-to-Treat gynecologic cancers?
Disease control Recruiting nowThis early-stage trial is testing an investigational drug called ARR-002 in adults with advanced or metastatic ovarian or endometrial cancer, including cases that have stopped responding to platinum-based chemotherapy. The main goals are to assess the drug's safety, tolerability,…
Phase 1 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New antibody takes aim at Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called CTIM-76 in people with advanced ovarian, testicular, or endometrial cancers that have not responded to standard treatments. CTIM-76 is a bispecific antibody designed to attach to a protein called Claudin-6 on cancer cells and he…
Phase 1 • Sponsor: Context Therapeutics Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug combo aims to keep ovarian cancer at bay longer
Disease control Recruiting nowThis phase 3 trial tests whether a new drug, sacituzumab tirumotecan, given with or without bevacizumab, can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer worsening. About 770 participants who have already completed two rounds of ch…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New combo therapy for endometrial cancer tested in Real-World setting
Disease control Recruiting nowThis study is tracking the safety and effectiveness of durvalumab (with or without olaparib) in about 50 Korean patients with endometrial cancer who are already prescribed these drugs. Researchers will follow participants for up to 12 months to see how well the treatment works in…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
BioNTech launches trial of BNT326 for advanced cancers
Disease control Recruiting nowThis study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…
Phase 1/2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug targets hard-to-treat cancers with missing MTAP gene
Disease control Recruiting nowThis early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…
Phase 1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug DSB2455 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called DSB2455 in adults with advanced cancers (breast, ovarian, prostate, pancreatic, or brain metastases) that have a specific DNA repair problem. The main goals are to check safety and see if the drug shrinks tumors. About 180 participan…
Phase 1 • Sponsor: Duke Street Bio Ltd • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Roche offers lifeline: continued cancer drug access for trial patients
Disease control Recruiting nowThis study gives people with cancer continued access to an experimental Roche treatment they were already receiving in a previous trial. It is for patients who still need the drug and cannot get it locally. The goal is to keep providing the treatment and monitor any side effects.
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a platform trial match the right drug combo to each tumor?
Disease control Recruiting nowThis phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…
Phase 1/2 • Sponsor: QuantumLeap Healthcare Collaborative • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug duo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called PYX-201 combined with pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 220 adults with certain cancers like head an…
Phase 1/2 • Sponsor: Pyxis Oncology, Inc • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for advanced cancers? first human trial of DS5361b begins
Disease control Recruiting nowThis early-phase study tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…
Phase 1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug NEOK001 targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-phase trial tests a new drug called NEOK001 in people with advanced solid tumors that have stopped responding to standard treatments. NEOK001 is designed to deliver a cancer-killing agent directly to tumor cells by targeting two specific proteins. The study will first …
Phase 1 • Sponsor: NEOK Bio, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New CAR T-Cell therapy takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental therapy called FT836, a ready-made CAR T-cell treatment, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers that have not responded to prior treatments. The main goals are…
Phase 1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can your Cancer's genes pick the right drug? TAPUR study aims to find out
Disease control Recruiting nowThe TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…
Phase 2 • Sponsor: American Society of Clinical Oncology • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug IMA402 targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.
Phase 1/2 • Sponsor: Immatics Biotechnologies GmbH • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug targets two cancer proteins in advanced tumors
Disease control Recruiting nowThis trial tests a new drug called VBC108 in people with advanced solid tumors that have not responded to standard treatments. VBC108 is designed to attach to two specific proteins (CLDN18.2 and CDH17) found on some cancer cells and deliver a toxic payload to kill them. The study…
Phase 1/2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug could protect children with cancer from chemo side effects
Disease control Recruiting nowThis study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.
Phase 2 • Sponsor: Spectrum Pharmaceuticals, Inc • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a targeted drug boost standard ovarian cancer therapy?
Disease control Recruiting nowThis trial is testing whether an experimental drug called TUB-040, when added to standard chemotherapy and a targeted therapy, is safe and tolerable for women with a specific type of advanced ovarian cancer. The study involves about 72 participants whose cancer has returned but s…
Phase 1/2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug IPN01195 enters human trials
Disease control Recruiting nowThis study tests a new drug called IPN01195 in about 85 adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have certain genetic changes in their …
Phase 1/2 • Sponsor: Ipsen • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for ovarian cancer: Rina-S faces off against chemo in major trial
Disease control Recruiting nowThis large Phase 3 trial will test a new drug called Rina-S, alone or with bevacizumab, against standard platinum-based chemotherapy for women with ovarian cancer that has returned after initial treatment. About 688 participants will be randomly assigned to receive either the new…
Phase 3 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New shot could make cancer treatment easier for patients with advanced tumors
Disease control Recruiting nowThis study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can one surgery treat endometrial cancer and obesity together?
Disease control Recruiting nowThis trial tests whether obese patients with endometrial cancer or a precancerous condition can safely undergo a hysterectomy and weight loss surgery at the same time. Researchers want to see if a fast-track referral process can get patients to surgery within 8 to 12 weeks of dia…
Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug cocktail aims to shrink recurrent ovarian tumors
Disease control Recruiting nowThis phase II trial tests an experimental drug called SYS6041, alone or combined with chemotherapy and other agents, in women whose ovarian cancer has returned. The study evaluates safety, the best dose, and how well the treatments shrink tumors. Participants must have a specific…
Phase 2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Tiny radioactive seeds may offer new hope for women with recurrent pelvic cancer
Disease control Recruiting nowThis study tests a radiation treatment called Cesium-131 brachytherapy for women whose cervical or endometrial cancer has returned in the vagina after prior pelvic radiation. Tiny radioactive seeds are placed directly into the tumor to kill cancer cells while sparing healthy orga…
Sponsor: Denise Fabian • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Fertility shield: new trial tests triptorelin to save ovaries during chemo
Disease control Recruiting nowThis phase 3 trial tests whether the drug triptorelin can protect the ovaries of adolescents and young adults with cancer who are receiving chemotherapy. Chemotherapy can damage the ovaries, making it hard or impossible to get pregnant later. Triptorelin temporarily pauses ovaria…
Phase 3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Experimental CAR t therapy takes on solid tumors in first human trial
Disease control Recruiting nowThis early-phase trial is testing a new immunotherapy called LEU011 for people with advanced solid tumors that have not responded to other treatments. LEU011 uses the patient's own immune cells, modified to better recognize and attack tumor cells. The study aims to find a safe do…
Phase 1/2 • Sponsor: Leucid Bio • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New hope for endometrial cancer: Mo-Rez drug faces chemo in major trial
Disease control Recruiting nowThis large Phase 3 study tests a new drug called mocertatug rezetecan (Mo-Rez) against standard chemotherapy for people with endometrial cancer that has progressed after platinum-based chemo and immunotherapy. About 600 participants will be randomly assigned to receive either Mo-…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat kidney cancer
Disease control Recruiting nowThis early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.
Phase 1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Electric pulses vs. pelvic tumors: a new hope when surgery fails?
Disease control Recruiting nowThis study looks at whether irreversible electroporation (IRE) can safely and effectively treat recurrent pelvic tumors in people who cannot have surgery, radiation, or other local treatments. IRE uses electrical pulses to destroy cancer cells without cutting or heating tissue. R…
Sponsor: Amsterdam UMC, location VUmc • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a triple-drug combo outsmart stubborn ovarian cancer?
Disease control Recruiting nowThis phase 2 trial tests whether combining disitamab vedotin, AK104, and bevacizumab can shrink tumors in people with recurrent or persistent clear cell ovarian cancer. Clear cell ovarian cancer is a rare and aggressive subtype that often stops responding to standard platinum-bas…
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can five radiation doses replace weeks of treatment for endometrial cancer?
Disease control Recruiting nowThis trial is testing whether a shorter, more intense course of radiation therapy can be a safe and effective option for people with high-risk endometrial cancer after surgery. Instead of the usual weeks of daily radiation, the study uses just five sessions of a higher dose, guid…
Sponsor: Instituto de Investigación Sanitaria Aragón • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Could fewer radiation sessions be just as effective for cervical cancer?
Disease control Recruiting nowThis phase III trial compares a shorter course of radiation therapy (hypofractionated) against the standard longer course for people with cervical cancer. Both groups also receive chemotherapy and brachytherapy. The goal is to see if the shorter schedule controls the cancer just …
Phase 3 • Sponsor: Mahidol University • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New injection YKYY031 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …
Phase 1 • Sponsor: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can fewer, stronger radiation doses ease treatment for gynecologic cancers?
Disease control Recruiting nowThis study is testing whether a shorter course of radiation therapy, given after surgery, can be as well-tolerated as the standard longer course for women with endometrial or cervical cancer. Instead of many small doses, the new approach uses five larger, precisely targeted doses…
Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New mRNA vaccine aims to stop ovarian Cancer's return
Disease control Recruiting nowThis early-stage trial tests a new mRNA cancer vaccine called CryptiVax-1001 in 50 women with advanced ovarian cancer. The vaccine is designed to train the immune system to recognize and attack cancer cells, potentially delaying or preventing the cancer from coming back. The main…
Phase 1 • Sponsor: Epitopea Ltd • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Could simple Over-the-Counter drugs supercharge cancer immunotherapy?
Disease control Recruiting nowThis study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…
Phase 2 • Sponsor: Val Adams • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill takes on advanced cancers in first human test
Disease control Recruiting nowThis early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…
Phase 1 • Sponsor: Groovy Medicine (Hangzhou) Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new immune drug outsmart Hard-to-Treat tumors?
Disease control Recruiting nowThis trial tests an experimental drug called STAR0602, which is designed to help the immune system attack cancer cells. It is being studied in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or combined with chemotherapy, …
Phase 1/2 • Sponsor: Marengo Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can robotic surgery match open surgery in beating cervical cancer?
Disease control Recruiting nowThis trial asks whether robot-assisted hysterectomy is as effective as traditional open surgery for treating early-stage cervical cancer. About 800 women with stage IB (excluding IB3) or IIA1 cervical cancer will be randomly assigned to one of the two surgical approaches. The mai…
Sponsor: Karolinska Institutet • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a Custom-Made immune cell vaccine turn the tide against solid tumors?
Disease control Recruiting nowThis trial tests a personalized approach to treating advanced solid tumors. Doctors take a patient's own immune cells, train them to recognize that patient's specific cancer mutations, and inject them back under the skin. The goal is to see if these customized cells can safely tr…
Sponsor: ZSky Biotech Inc • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
A simple drain may slash wound infections after gynecologic cancer surgery
Disease control Recruiting nowThis trial tests whether placing a small closed-suction drain under the skin before closing the incision can reduce wound complications in women with thick subcutaneous tissue (2.5 cm or more) undergoing midline abdominal surgery for gynecologic cancer. Half of the participants w…
Sponsor: Mahmut Yassa • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Robot or scalpel? a Head-to-Head trial for cervical cancer surgery
Disease control Recruiting nowThis trial compares two surgical approaches for early-stage cervical cancer: robotic-assisted surgery using the da Vinci system versus traditional open surgery. Researchers are asking whether the minimally invasive robotic method can match or improve upon open surgery in terms of…
Sponsor: GOG Foundation • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can heated chemo during surgery help older women with ovarian cancer?
Disease control Recruiting nowThis study tests whether giving heated chemotherapy directly into the abdomen during surgery is safe for women aged 70 and older with advanced ovarian cancer. The treatment, called NIPEC with carboplatin, is delivered at normal body temperature for 90 minutes right after the surg…
Phase 1 • Sponsor: Odense University Hospital • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
A new care pathway aims to get cancer surgery patients home safer and faster
Disease control Recruiting nowThis large trial tests whether a structured program called RESET can improve outcomes for adults undergoing planned cancer surgery. RESET combines pre-surgery preparation (prehabilitation), enhanced in-hospital recovery practices, and personalized support after discharge. Researc…
Sponsor: Regional Specialist Hospital in Wroclaw • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Exercise and diet counseling may help cancer patients finish chemo
Disease control Recruiting nowThis study tests whether a program of exercise and nutrition counseling helps women with ovarian or endometrial cancer stick with their chemotherapy plan. About 200 women who are about to start chemotherapy will be randomly assigned to either receive weekly coaching sessions on p…
Sponsor: Yale University • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Engineered virus targets Hard-to-Treat cancers from the inside
Disease control Recruiting nowThis study tests an experimental therapy called YH02, a genetically modified virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors in people with advanced solid tumors (such as head and neck cancer, breast cancer, or melanoma) that ha…
Phase 2 • Sponsor: Tianjin First Central Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Radiation boost may Re-Sensitize ovarian cancer to PARP inhibitors
Disease control Recruiting nowThis phase 2 trial investigates whether adding stereotactic body radiotherapy (SBRT) to the PARP inhibitor niraparib can improve control of ovarian cancer that has spread to a limited number of new spots after prior PARP inhibitor therapy. Participants will receive SBRT alone or …
Phase 2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Tailored rehab program aims to help young adults reclaim life after cancer
Disease control Recruiting nowThis trial tests a 16-week rehabilitation program called YATAC, designed specifically for young adults aged 18–39 who have or have had cancer. The program includes physical activity, mental health support, nutrition advice, and help with education or work. Researchers want to see…
Sponsor: University of Aarhus • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Exercise after cancer: could resistance training rebuild bodies?
Disease control Recruiting nowThis study tests whether a closely supervised resistance training program can improve functional mobility, body composition, and strength in people who have been treated for cancer. Participants aged 20 to 89 will follow a structured exercise regimen during or after their cancer …
Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Zapping resistant tumors may extend life of cancer drugs
Disease control Recruiting nowThis study tests whether adding a precise local treatment—like focused radiation or ablation—can help people whose cancer has a few new or growing spots while on standard therapy. Participants continue their usual medication while the resistant tumors are treated directly. The go…
Sponsor: University of California, Davis • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Radiation that adapts daily: a smarter way to hit tumors and spare organs
Disease control Recruiting nowThis trial tests a new radiation technique for people with abdominal or pelvic tumors. Standard radiation gives the same dose each session, but this approach adjusts the dose daily based on the exact position of the tumor and nearby organs. The goal is to deliver more radiation t…
Sponsor: University of Zurich • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Can a mesh shield ovarian cancer patients from painful hernias?
Disease control Recruiting nowThis trial tests whether placing a surgical mesh during abdominal closure can prevent incisional hernias in women undergoing ovarian cancer surgery. It also examines if a negative pressure wound dressing reduces infection risk. Participants are randomly assigned to one of four gr…
Sponsor: Hospital Vall d'Hebron • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Can cervical cancer patients stop immunotherapy early? new study investigates
Disease control Recruiting nowThis study follows 261 people with persistent, recurrent, or metastatic cervical cancer who are taking pembrolizumab (Keytruda) with or without bevacizumab (Avastin). Some participants may choose to stop pembrolizumab early if their tumor shrinks or disappears, while others conti…
Phase 4 • Sponsor: University Medical Center Groningen • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New cocktail of old drugs takes on advanced cancers
Disease control Recruiting nowThis Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…
Phase 2 • Sponsor: Sarcoma Oncology Research Center, LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers with rare TP53 mutation
Disease control Recruiting nowThis study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …
Phase 1/2 • Sponsor: Nutshell Therapeutics (Shanghai) Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could injecting immunotherapy into lymph nodes boost cervical cancer treatment?
Disease control Recruiting nowThis early-stage trial explores whether injecting the immunotherapy drug nivolumab directly into lymph nodes before standard surgery is feasible and safe for people with cervical cancer. The study involves 12 participants and aims to see if this targeted approach can shrink tumor…
Phase 1 • Sponsor: University Medical Center Groningen • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a 3-Week radiation course beat the standard 5-Week for cervical cancer?
Disease control Recruiting nowThis study tests whether a shorter, 3-week course of radiation works as well as the standard 5-week course for women with locally advanced cervical cancer. About 396 women will be randomly assigned to one of the two schedules, both combined with chemotherapy. If the shorter sched…
Sponsor: All India Institute of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Dual immunotherapy plus chemo may shrink cervical tumors before surgery
Disease control Recruiting nowThis phase 2 trial is testing a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy before surgery in 103 women with locally advanced cervical cancer. The goal is to see if this approach can shrink tumors enough to allow less extensive…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New biologic JLM019 enters human testing for advanced cancers
Disease control Recruiting nowThis early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …
Phase 1 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Ovarian cancer surgery showdown: tumor removal vs. bowel resection
Disease control Recruiting nowThis study looks at two different surgeries for advanced ovarian cancer that has spread to the bowel. One method removes only the tumor from the bowel, while the other removes a piece of the bowel along with the tumor. The goal is to see which approach helps patients live longer …
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Simple blood test could spot cancer earlier in symptomatic patients
Diagnosis Recruiting nowThis study is testing two new blood tests designed to help doctors detect cancer in people who have symptoms that might be cancer. The study will involve 1,650 adults aged 45 and older who are already undergoing medical tests for possible cancer. The goal is to see how well these…
Sponsor: Harbinger Health • Aim: Diagnosis
Last updated Sep 21, 2026 17:00 UTC
-
New scan could reveal how well your immune system fights cancer
Diagnosis Recruiting nowThis study tests an experimental imaging agent (89Zr-DFO-REGN5054) that may help visualize immune cells called CD8+ T cells in tumors. About 50 people with advanced solid cancers will receive the imaging agent along with the immunotherapy drug cemiplimab. The main goal is to chec…
Phase 1 • Sponsor: Regeneron Pharmaceuticals • Aim: Diagnosis
Last updated Sep 21, 2026 17:00 UTC
-
Can AI learn to spot endometriosis and fibroids on ultrasound?
Diagnosis Recruiting nowResearchers at Semmelweis University are building and testing artificial intelligence algorithms that read standardized transvaginal ultrasound images. The study includes women aged 18 to 45 who have suspected endometriosis or adenomyosis, a confirmed uterine mass scheduled for s…
Sponsor: Semmelweis University • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Can a new vaginal scanner map tumors and cut MRI reliance?
Diagnosis Recruiting nowResearchers at University Health Network in Toronto are testing a device called Vagina-View to see if it can clearly show vaginal tumor tissue and help position a brachytherapy applicator during treatment for vaginal cancer. Ten participants with gynecological cancer who are sche…
Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Cervical smear DNA may reveal ovarian cancer years before symptoms
Diagnosis Recruiting nowHigh-grade serous ovarian cancer is often found too late, and no screening test exists. Researchers are studying whether DNA taken from routine cervical smears can show signs of this cancer early. They use a method called shallow-coverage whole genome sequencing to look for genom…
Sponsor: Institut Claudius Regaud • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
New PET tracer aims to spot hidden cancer spread in the abdomen
Diagnosis Recruiting nowThis phase 2 study tests whether a radioactive tracer called [68Ga]BED003 can improve PET/CT scans for detecting cancer in the peritoneum (the lining of the abdomen). The trial includes adults with colorectal, ovarian, gastric, pancreatic, or a type of breast cancer. Researchers …
Phase 2 • Sponsor: Blue Earth Diagnostics • Aim: Diagnosis
Last updated Sep 17, 2026 00:00 UTC
-
Blood test aims to catch Cancer's return earlier
Diagnosis Recruiting nowThe ORACLE study watches people who have finished treatment for early-stage solid tumors, such as lung, breast, colon, and pancreatic cancers. Researchers want to see if a blood test called Guardant Reveal can find tiny traces of tumor DNA that might signal the cancer is coming b…
Sponsor: Guardant Health, Inc. • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
Can a simple rinse reveal ovarian Cancer's earliest signs?
Diagnosis Recruiting nowThis study explores whether a uterine lavage—a procedure that rinses the fallopian tubes with saline to collect cells—can help detect early genetic changes linked to ovarian cancer in women with BRCA mutations. Participants are high-risk women planning risk-reduction surgery. Res…
Sponsor: University of Washington • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
One blood draw, many cancers: AI model aims to spot tumors early
Diagnosis Recruiting nowResearchers are developing a blood test that uses DNA methylation patterns and machine learning to detect multiple types of cancer at an early stage. The PROFOUND study collects blood samples from people newly diagnosed with cancer and from people without a confirmed cancer diagn…
Sponsor: Shanghai Weihe Medical Laboratory Co., Ltd. • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
Glowing dye could light up leftover cancer cells at surgery edges
Diagnosis Recruiting nowResearchers at Erasmus Medical Center are testing whether a fluorescent imaging agent can highlight cancer cells on the surface of tumor tissue removed during surgery. The study involves 200 adults with solid tumors who are scheduled for surgery. After the tumor is removed, the d…
Sponsor: Erasmus Medical Center • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
Can a personalised tool sharpen ovarian cancer risk prediction?
Diagnosis Recruiting nowResearchers are comparing two ways to assess ovarian cancer risk in people who are cancer-free but may be at higher risk because of family history or genetics. One approach follows standard national guidelines, using family history and sometimes genetic testing. The other uses th…
Sponsor: Instituto Portugues Oncologia de Lisboa Francisco Gentil • Aim: Diagnosis
Last updated Sep 11, 2026 00:00 UTC
-
Can a new PET tracer reveal hidden tau in the brain?
Diagnosis Recruiting nowThis study tests whether a radioactive tracer called 18F-S16/T807 can help diagnose tau-related brain diseases. Tau is a protein that builds up abnormally in conditions like Alzheimer's and other neurodegenerative disorders. Researchers will give 500 adults a single injection of …
Sponsor: Tianjin Medical University • Aim: Diagnosis
Last updated Sep 10, 2026 00:00 UTC
-
Can a brain scan reveal the hidden amyloid behind neurodegenerative disease?
Diagnosis Recruiting nowThis study tests whether PET/CT scans using two radioactive tracers, 18F-92/AV45 and 11C-PIB, can detect beta amyloid buildup in the brain. Researchers will enroll 500 adults with suspected or known neurodegenerative diseases linked to amyloid. Each participant receives one injec…
Sponsor: Tianjin Medical University • Aim: Diagnosis
Last updated Sep 10, 2026 00:00 UTC
-
New scan could reveal hidden cancers in PD-L1 patients
Diagnosis Recruiting nowThis study is testing a special type of PET/CT scan that looks for a protein called PD-L1 on cancer cells. The goal is to see if this scan can find tumors and their spread more accurately than standard imaging. About 500 adults with suspected or known PD-L1-related cancers will r…
Sponsor: Tianjin Medical University • Aim: Diagnosis
Last updated Sep 10, 2026 00:00 UTC
-
A new imaging tracer may reveal hidden nerve injuries
Diagnosis Recruiting nowThis trial tests whether an injected tracer called HED, seen on PET/CT or MRI scans, can help diagnose diseases of the sympathetic nervous system, the part of the body that controls automatic responses like heart rate and blood pressure. Researchers will scan 500 adults who have …
Sponsor: Tianjin Medical University • Aim: Diagnosis
Last updated Sep 10, 2026 00:00 UTC
-
Can repeated MRI scans reveal how tumors respond to radiation?
Diagnosis Recruiting nowThis study tests whether taking multiple MRI scans before, during, and after standard radiation therapy can help doctors see how tumors change. Researchers will enroll people with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer, or pediatric glioma. The g…
Sponsor: Dana-Farber Cancer Institute • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
Blood test may spot cervical cancer without a biopsy
Diagnosis Recruiting nowThis trial tests whether a simple blood test can help detect and monitor cervical cancer. Researchers will analyze tiny DNA fragments and particles in the blood, called cell-free DNA and extracellular vesicles, to see if they act as early warning signs. The study involves 100 wom…
Sponsor: Queensland Centre for Gynaecological Cancer • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
New blood test could spot 10 cancers before symptoms start
Diagnosis Recruiting nowThis study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…
Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
Can a new PET tracer light up hidden cancers?
Diagnosis Recruiting nowThis trial is testing whether a new radioactive tracer, called 68Ga-SorB, can help doctors see certain solid tumors on PET/CT scans. The tracer targets sortilin, a protein that is often found on cancer cells. About 50 adults with melanoma, liver, lung, breast, pancreatic, or ovar…
Sponsor: Peking University Third Hospital • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva
Diagnosis Recruiting nowThis study evaluates a rapid test called Methylscape that measures DNA methylation patterns in body fluids like blood, urine, or saliva. The goal is to see if it can detect a cancer signal and even predict where the cancer started, using a single sample. Researchers will compare …
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Could a simple estrogen treatment sharpen the view for cervical cancer screening?
Diagnosis Recruiting nowThis trial tests whether applying vaginal estrogen before a colposcopy helps doctors see the cervix more clearly in women aged 50 and older. As women age, the area where precancerous changes occur can become harder to view, which may lead to missed diagnoses or repeat procedures.…
Sponsor: University of Aarhus • Aim: Diagnosis
Last updated Aug 02, 2026 00:00 UTC
-
Could a simple blood test replace invasive tissue biopsies for cancer genetics?
Diagnosis Recruiting nowThis study compares a blood test (liquid biopsy) to the standard tissue biopsy for finding genetic changes in advanced solid tumors. The goal is to see if the liquid biopsy can accurately detect the same genetic alterations as the tissue sample. If it works, patients might avoid …
Sponsor: Centre Antoine Lacassagne • Aim: Diagnosis
Last updated Jul 22, 2026 00:00 UTC
-
Simple blood test aims to spot multiple cancers early
Diagnosis Recruiting nowThis study collects blood samples from healthy people, those with benign diseases, and cancer patients to develop a multi-analyte blood test. The test looks for DNA methylation markers that may indicate the presence of various cancers, especially liver cancer. Researchers aim to …
Sponsor: Helio Genomics • Aim: Diagnosis
Last updated Jul 12, 2026 00:00 UTC
-
HPV DNA test could slash cervical cancer deaths in High-Risk populations
Diagnosis Recruiting nowThis study evaluates whether an HPV DNA test can more accurately detect pre-cancerous cervical changes than standard Pap smears in 1,500 women in South Africa, including those with and without HIV. Participants undergo HPV testing, followed by colposcopy and biopsy if needed. The…
Sponsor: University of Pretoria • Aim: Diagnosis
Last updated Jul 09, 2026 00:00 UTC
-
New scan technique could sharpen tumor targeting during radiation
Diagnosis Recruiting nowThis study tests whether a special CT scan with contrast dye can give clearer images of tumors during radiation therapy. Twenty adults with advanced cancer will receive the extra scan alongside their standard treatment. The goal is to see if this approach is feasible and improves…
Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
Vaginal fluid may hold key to early cancer detection
Diagnosis Recruiting nowThis study looks at whether vaginal fluid can help detect gynaecological cancers early. Researchers will collect samples from 250 women, including those with and without cancer, to compare specific markers. The goal is to develop a non-invasive test that could improve detection a…
Sponsor: University Hospital Southampton NHS Foundation Trust • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
Can a virtual promotora get more hispanic women screened for cervical cancer?
Prevention Recruiting nowResearchers at Florida A&M University are testing whether a virtual educational session led by a lay health advisor, called a promotora, helps Hispanic women who are behind on cervical cancer screening get tested. The trial enrolls about 160 Hispanic women ages 21 to 65 who have …
Sponsor: Florida A&M University • Aim: Prevention
Last updated Sep 21, 2026 17:00 UTC
-
Can a gentler blood thinner shield cancer patients from new clots?
Prevention Recruiting nowCancer patients with a central catheter can develop a blood clot in the upper arm. After at least three months of standard blood-thinning treatment, this trial tests whether switching to a lower, preventive dose of apixaban can stop new clots from forming. Participants stay on th…
Phase 4 • Sponsor: Ottawa Hospital Research Institute • Aim: Prevention
Last updated Sep 21, 2026 17:00 UTC
-
Cheap statin could slash deadly clot risk in cancer patients
Prevention Recruiting nowThis study tests whether taking a daily statin (rosuvastatin) for one year can safely prevent life-threatening blood clots in people with cancer. Current clot-preventing drugs raise bleeding risks, so a safer option is needed. The trial will enroll 4,000 adults with newly diagnos…
Phase 4 • Sponsor: Brigham and Women's Hospital • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
New shot could stop deadly clots in cancer patients
Prevention Recruiting nowThis phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Prevention
Last updated Sep 17, 2026 00:00 UTC
-
Can a new drug shield nerves from Chemotherapy's side effects?
Prevention Recruiting nowThis phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…
Phase 2 • Sponsor: Sironax USA, Inc. • Aim: Prevention
Last updated Sep 03, 2026 00:00 UTC
-
A genetic score could sharpen breast cancer risk prediction
Prevention Recruiting nowThis study tests whether adding a polygenic risk score (PRS) — a measure based on 313 genetic markers — to the standard CanRisk model can improve breast cancer risk prediction and prevention. About 100 women at increased risk will receive genetic counseling, a blood draw, and the…
Sponsor: Catholic University of the Sacred Heart • Aim: Prevention
Last updated Aug 05, 2026 00:00 UTC
-
At-Home HPV tests could boost cervical cancer screening in border communities
Prevention Recruiting nowThis study tests whether at-home HPV self-sampling (using urine or a vaginal swab) can help more people get screened for cervical cancer compared to the traditional in-clinic Pap smear. About 735 Latinx individuals aged 30-65 who haven't had a Pap test in at least three years wil…
Sponsor: University of Texas at Austin • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
New support program aims to help cancer patients finish treatment and feel better
Symptom relief Recruiting nowThis study tests a program called ICCAN that gives cancer patients extra help with social and economic needs, like finding resources and monthly check-ins. Researchers want to see if this support helps patients complete their cancer treatment and improves their quality of life, c…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Sep 21, 2026 17:00 UTC
-
Prepping for surgery: could exercise and diet before the knife cut complications?
Symptom relief Recruiting nowThis study looks at whether a prehabilitation program—including physical therapy, dietary advice, and emotional support—given before major cancer surgery can reduce deaths and serious complications within 30 days after the operation. About 180 adults with cancers of the pancreas,…
Sponsor: Fox Chase Cancer Center • Aim: Symptom relief
Last updated Sep 21, 2026 17:00 UTC
-
Matching cancer survivors to the right level of support
Symptom relief Recruiting nowResearchers at the University of Hong Kong are evaluating a survivorship program that sorts cancer patients into moderate or high needs after treatment. People with moderate needs receive weekly or bi-weekly e-intervention videos on managing distress and weight, with peer volunte…
Sponsor: The University of Hong Kong • Aim: Symptom relief
Last updated Sep 21, 2026 17:00 UTC
-
New surgery showdown: which technique best stops phantom limb pain?
Symptom relief Recruiting nowThis pilot study tests two surgical methods—targeted muscle reinnervation (TMR) and regenerative peripheral nerve interfaces (RPNI)—alone and together to reduce chronic and phantom limb pain in cancer patients who have had an amputation. About 45 adults will be randomly assigned …
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 21, 2026 17:00 UTC
-
Pre-Radiation pelvic therapy may ease pain and sexual issues for women with pelvic cancers
Symptom relief Recruiting nowThis study looks at whether adding pelvic floor physical therapy before standard radiation treatment can help reduce pain and sexual problems in women with cervical, vaginal, vulvar, uterine, or anal cancer. About 20 participants will receive education on using a vaginal dilator …
Sponsor: Indiana University • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
New proton therapy aims to reduce bowel side effects in gynecologic cancer patients
Symptom relief Recruiting nowThis study is testing a precise type of radiation (proton beam) given to the pelvis after surgery for cervical, uterine, or endometrial cancer. The goal is to see if it causes fewer bowel side effects than standard radiation. About 25 adults who need pelvic radiation after surger…
Phase 2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Massage during chemo: a new way to fight anxiety?
Symptom relief Recruiting nowThis study tests whether different types of massage can lower anxiety in cancer patients while they receive chemotherapy. Fifty adults who already have high anxiety and are at least one cycle into chemo will receive massage during their infusion sessions. Researchers will measure…
Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Can zoom therapy ease Cancer's emotional toll? new study tests Meaning-Centered groups
Symptom relief Recruiting nowThis study is testing whether a virtual, 8-session group therapy program can help cancer patients find meaning and reduce emotional distress. Researchers at MD Anderson Cancer Center will enroll 72 adults with a history of cancer. Participants will attend weekly 90-minute session…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New shorter radiation may ease side effects for cancer patients
Symptom relief Recruiting nowThis study tests if a newer, shorter course of radiation therapy (MH-ART) is as good as the standard longer course (CF-IMRT) for women who have had surgery for cervical or endometrial cancer. The goal is to see if the new approach causes fewer side effects and improves quality of…
Sponsor: Xiaorong Hou • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New 'Lattice' radiation aims to zap tumor pain better than standard therapy
Symptom relief Recruiting nowThis phase 3 trial compares lattice radiation therapy (LRT) to standard radiation for reducing pain from large solid tumors (at least 5 cm). About 148 adults whose tumors cannot be surgically removed will be randomly assigned to one of the two radiation approaches. The main goal …
Phase 3 • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Smartwatch workouts aim to beat Post-Chemo fatigue
Symptom relief Recruiting nowThis study tests whether a personalized exercise program, tracked by a smartwatch, can help reduce fatigue in people who have finished chemotherapy for certain cancers (breast, colorectal, ovarian, pancreatic, or gastric). About 98 participants will be randomly assigned to either…
Sponsor: Centre Antoine Lacassagne • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
New shot aims to ease depression and anxiety in cancer and chronic disease patients
Symptom relief Recruiting nowThis study tests whether a single injection of RE104 can reduce symptoms of depression or mixed depression and anxiety in people with adjustment disorder caused by a serious medical illness like cancer, ALS, multiple sclerosis, Parkinson's disease, or idiopathic pulmonary fibrosi…
Phase 2 • Sponsor: Reunion Neuroscience Inc • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
New IV combo aims to stop chemo sickness in kids
Symptom relief Recruiting nowChemotherapy often causes nausea and vomiting, which is especially hard for children. This study tests a new IV drug called NEPA (fosnetupitant/palonosetron) to prevent these side effects in kids with cancer. The trial has two parts: first, an open-label phase to find the right d…
Phase 2 • Sponsor: Helsinn Healthcare SA • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
AI app aims to boost cancer Patients' mood and quality of life
Symptom relief Recruiting nowThis study tests whether an artificial intelligence (AI) app can improve quality of life, anxiety, and depression in people with cancer who are already receiving psychotherapy. About 60 participants will be randomly assigned to either get the AI app alongside their usual therapy …
Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
New hope for cancer patients suffering from severe diarrhea and colitis from immunotherapy
Symptom relief Recruiting nowThis study tests if the drug ustekinumab can control diarrhea and colon inflammation caused by immune checkpoint inhibitors in cancer patients. Ten adults with solid tumors who have moderate to severe symptoms will receive ustekinumab and be monitored for side effects and symptom…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Tailored Pre-Surgery workouts could help seniors with cancer recover faster
Symptom relief Recruiting nowThis pilot study tests a 4-week personalized exercise program for people aged 70 and older who are about to have cancer surgery. Participants follow daily exercises at home using a smartphone app. The goal is to see if this approach improves their physical fitness before the oper…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Amazon plant put to the test against Cancer's relentless tiredness
Symptom relief Recruiting nowCancer treatment often leaves patients with a deep, lasting tiredness that few treatments can fix. Researchers are testing whether guarana, a caffeine-rich Amazonian plant, can reduce that fatigue and improve daily life. The study gives 60 people with breast, lung, colorectal, ce…
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
New telehealth program aims to ease depression and fatigue in latino cancer patients
Symptom relief Recruiting nowThis study tests a special mental health program called DESCANSO/REST for Spanish-speaking Latino cancer patients who feel depressed, tired, or have trouble sleeping. The program is delivered through telehealth (video or phone calls). Researchers want to see if it is practical an…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
New study tests Home-Based exercise and brain games for cancer Survivors' memory woes
Symptom relief Recruiting nowThis pilot study is testing a combined program of mobile health exercise and cognitive rehabilitation for older cancer survivors (age 60+) who have concerns about memory or thinking after treatment. The program uses a smartphone app for exercise tracking and group workshops for b…
Sponsor: University of Rochester • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
AI chatbot could help gynecologic cancer survivors reclaim sexual health
Symptom relief Recruiting nowResearchers in Taiwan are testing LillyBot, an AI chatbot that provides personalized sexual health education and consultation for women who have had gynecologic cancer. The trial will enroll 90 survivors and compare two versions of the system, one with proactive nurse contact and…
Sponsor: Chang Gung Memorial Hospital • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Virtual reality goggles ease pain for kids with cancer
Symptom relief Recruiting nowThis study tests whether using a virtual reality helmet during painful medical procedures (like needle sticks or bone marrow tests) can reduce pain in children with cancer. About 74 children aged 6 to 18 will be split into two groups: one gets standard care plus the VR helmet, th…
Sponsor: Centre Hospitalier Universitaire de la Réunion • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Magic mushroom therapy targets Cancer-Related depression
Symptom relief Recruiting nowThis phase 2 trial at MD Anderson Cancer Center is testing whether psilocybin-assisted psychotherapy can safely help ease depression and anxiety in 30 adults with advanced cancer who are on maintenance therapy. Participants receive either psilocybin or a placebo (niacin) along wi…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
New program aims to cut hospital visits by helping cancer patients speak up
Symptom relief Recruiting nowThis trial tests an educational program called A-PACT for people with solid tumors who are at high risk of decline. Trained lay health workers coach patients on how to discuss their care goals and end-of-life wishes with their medical team. The study will see if this reduces unpl…
Sponsor: SWOG Cancer Research Network • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Massage during chemo: a new way to ease cancer treatment stress?
Symptom relief Recruiting nowThis small study will test whether giving a 15-20 minute massage during infusion therapy can reduce pain and anxiety in women with gynecologic cancer. Twenty-four participants will be randomly assigned to receive either a hand, foot, or neck/shoulder massage or simply talk with t…
Sponsor: Jill Cole • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Can a buddy system help older cancer patients? new study says maybe
Symptom relief Recruiting nowThis study tests a 4-month coaching program called SONATA that helps older adults (age 60+) with advanced cancer build a support network of family and friends. The goal is to see if this social support makes it easier to stick with treatment and feel better. About 330 patients an…
Sponsor: University of Rochester • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Walking and memory games may boost brain power in older cancer survivors
Symptom relief Recruiting nowThis study tests whether a walking program and cognitive rehabilitation exercises can improve memory and thinking in people aged 65 and older who have finished cancer treatment. Forty participants will be randomly assigned to one of four groups: exercise only, cognitive training …
Sponsor: University of Rochester • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Can phone Check-Ins ease cancer treatment side effects?
Symptom relief Recruiting nowThis study tests whether regular phone check-ins and counseling can help people on oral cancer drugs feel better and avoid hospital visits. 600 patients will be assigned to symptom monitoring alone, or monitoring plus a self-help handbook and phone counseling for anxiety or sadne…
Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
New online therapy aims to ease cancer Survivors' mental health struggles
Symptom relief Recruiting nowThis study tests an online, therapist-guided program to help cancer survivors who have anxiety, depression, or fear of cancer returning. About 400 adults in Sweden who finished cancer treatment at least 6 months ago will take part. The goal is to see which parts of the 10-week on…
Sponsor: Karolinska Institutet • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Can an antidepressant calm Chemotherapy's nerve pain?
Symptom relief Recruiting nowThis trial tests whether duloxetine, a drug commonly used for depression, can reduce the painful nerve damage that some cancer patients experience after receiving taxane chemotherapy. The study enrolls adults with solid tumors who have at least moderate pain from this side effect…
Phase 2 • Sponsor: Yan Yang, MD, Ph.D • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
New therapy aims to ease spiritual distress in latino cancer patients
Symptom relief Recruiting nowThis study adapts a counseling program called Meaning Centered Psychotherapy for Latinos with advanced cancer. The goal is to improve spiritual well-being and quality of life. Researchers will enroll 190 Latino adults with stage III or IV solid tumors to test the program's feasib…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
Magic mushroom therapy targets cancer fear in remission patients
Symptom relief Recruiting nowThis early-phase study tests whether psilocybin (the active ingredient in magic mushrooms) combined with talk therapy can reduce fear of cancer returning in 20 women with early-stage breast or ovarian cancer who are currently in remission. Participants receive a moderately high d…
Phase 1 • Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
New Clot-Busting procedure could ease breathing for cancer patients
Symptom relief Recruiting nowThis study looks at whether a computer-assisted vacuum procedure to remove blood clots from the lungs is safe and improves quality of life for cancer patients with a moderate-risk pulmonary embolism. About 25 adults with cancer and a confirmed clot in a major lung artery will tak…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
New pill aims to stop chemo sickness in its tracks
Symptom relief Recruiting nowThis study tests an experimental drug called LY3537021 to see if it can better control nausea and vomiting caused by chemotherapy in adults with cancer. About 204 participants will receive either the drug or a placebo, and researchers will track who has no vomiting and does not n…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
New study monitors eye health in cervical cancer drug TIVDAK
Symptom relief Recruiting nowThis study looks at possible eye-related side effects in people with cervical cancer that has returned or spread, who are being treated with the drug TIVDAK. About 100 participants will receive TIVDAK every 3 weeks and undergo regular eye exams before, during, and after treatment…
Phase 4 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Could a simple activity-based therapy lift depression in older cancer survivors?
Symptom relief Recruiting nowThis study tests whether a short psychotherapy called brief behavioral activation (BBA) can reduce depression and anxiety and improve well-being in older adults who have survived cancer. BBA encourages people to set goals and engage in enjoyable or rewarding activities to change …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
Free money for cancer patients: $1,000 monthly cash cards tested in new study
Symptom relief Recruiting nowThis pilot study will give 20 early-stage cancer patients a preloaded cash card with $1,000 each month. The goal is to see if this simple cash support can prevent financial hardship, like debt or missed rent, and improve treatment outcomes. Researchers will measure how many peopl…
Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
Could a simple supplement protect your gut during radiation?
Symptom relief Recruiting nowThis study tests whether taking a short chain fatty acid supplement can reduce gut-related side effects in people receiving radiation therapy for cancers in the abdomen or pelvis. About 122 adults will be randomly assigned to receive either the supplement or a placebo. The goal i…
Phase 1/2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
A simple talk could ease cancer Patients' anxiety
Symptom relief Recruiting nowThis study tests whether a single early meeting with a psycho-oncology counselor can reduce anxiety and depression and improve quality of life in people recently diagnosed with cancer. About 148 patients will be randomly assigned to either receive this counseling plus standard ca…
Sponsor: Lindenhofgruppe AG • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Can acupuncture needles help bladder recovery after cancer surgery?
Symptom relief Recruiting nowThis study looks at whether electroacupuncture (a type of acupuncture with mild electric pulses) can help women who have trouble urinating after surgery for cervical cancer. About 208 participants will receive either real or fake electroacupuncture alongside standard care. The ma…
Sponsor: Lu Chao • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Cancer care goes home: study tests nurse visits to cut hospital trips
Symptom relief Recruiting nowThis study is testing a new way to manage care for 33 cancer patients who take oral chemotherapy at home. Instead of going to the hospital every month just to pick up medicine, a nurse will visit them at home twice in six months. An advanced practice nurse will coordinate everyth…
Sponsor: Institut Claudius Regaud • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
New study tests coaching to boost Pill-Taking in young cancer patients
Symptom relief Recruiting nowThis study tests whether a tailored coaching program can help adolescents and young adults (ages 15-24) with cancer take their oral medications as prescribed. Participants will work with a coach over four sessions to identify and overcome barriers to adherence, using an electroni…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
A new program aims to ease cancer survivors' fear of recurrence
Symptom relief Recruiting nowThis trial tests a program that screens cancer survivors for fear of recurrence and refers those who need help to psychological services. The program is being rolled out in cancer clinics in Hong Kong, with nurses trained to identify at-risk patients. Researchers will measure how…
Sponsor: The University of Hong Kong • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Can a virtual buddy system get older cancer patients moving?
Symptom relief Recruiting nowThis study tests whether a virtual exercise program with peer support helps older adults (60+) with cancer become more active and feel better. Participants are matched with a peer and receive guidance from exercise professionals or just peer support, compared to usual care. Over …
Phase 2/3 • Sponsor: McMaster University • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Vibrating device aims to restore bladder control in cancer survivors
Symptom relief Recruiting nowThis pilot study tests whether a device called Flyte can help improve urinary incontinence in women who had radiation therapy for endometrial or cervical cancer. The Flyte device is used at home and delivers gentle vibrations while the user does Kegel exercises. The study will ch…
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Can a simple pill make cervical cancer screening more effective?
Symptom relief Recruiting nowThis study tests whether the drug misoprostol, given before a cervical exam, can help doctors see the cervix more clearly. 420 women with a hard-to-examine cervix (called Type 3 transformation zone) will receive either misoprostol or a placebo. The goal is to see if the drug make…
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
A new approach to tame the fear that lingers after cancer
Symptom relief Recruiting nowThis trial tests a stepped-care program to help cancer survivors manage fear of their cancer returning. The program starts with an online intervention called eConquerFear, which teaches strategies to control worry and accept uncertainty. If needed, participants receive additional…
Sponsor: The University of Hong Kong • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Cactus extract could zap cancer pain in new trial
Symptom relief Recruiting nowThis early-stage study tests a drug called resiniferatoxin (RTX), a chemical from a cactus-like plant similar to hot pepper, for people with severe cancer pain that standard treatments can't control. RTX is injected into the spine to destroy pain-transmitting nerves. The trial in…
Phase 1 • Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Heat therapy as a palliative aid: does raising body temperature ease advanced cancer symptoms?
Symptom relief Recruiting nowThis study looks at whether a noninvasive treatment called whole-body infrared hyperthermia can help people with advanced solid tumors feel better. The therapy uses infrared energy to raise body temperature in a controlled way, and researchers will track changes in pain, fatigue,…
Sponsor: Zhejiang Hospital • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC
-
Digital brain training may ease 'chemo brain' — a trial puts it to the test
Symptom relief Recruiting nowThis trial tests whether two types of home-based digital cognitive training can help cancer survivors who have memory, attention, or thinking problems after chemotherapy. Participants will use either a computer program (BrainHQ) or a virtual reality cognitive training for 10 week…
Sponsor: Biogipuzkoa Health Research Institute • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Digital navigator aims to cut financial toxicity for young adults with cancer
Symptom relief Recruiting nowThis pilot study tests a hybrid intervention that combines a digital platform (Findhelp.org) with human navigation sessions to help adolescent and young adult cancer survivors manage financial and health-related social needs. Researchers will refine the approach with input from s…
Sponsor: Columbia University • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
Could a homeopathic remedy ease cancer treatment fatigue?
Symptom relief Recruiting nowThis study tests whether a homeopathic product called Encer can reduce fatigue in people with solid tumors who are starting chemotherapy or radiation therapy. Participants are randomly assigned to receive either Encer or a placebo, and their fatigue levels are tracked using a que…
Early phase 1 • Sponsor: Beaura for Para Pharmaceutical Products Trading LLC • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Spinal pain pump may offer relief for cancer patients when opioids fail
Symptom relief Recruiting nowThis trial tests whether a small pump implanted in the abdomen that delivers pain medicine directly to the spinal fluid can improve quality of life for people with severe cancer pain that is not controlled by oral opioids. Participants are randomly assigned to get the pump or to …
Sponsor: Universitair Ziekenhuis Brussel • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Lifestyle coaching may boost quality of life for cancer patients
Symptom relief Recruiting nowThis study tests whether a combined lifestyle program—focusing on nutrition, physical activity, sleep, stress, and sense of purpose—can improve quality of life for people with cancer. It includes cancer survivors within five years of curative treatment and those with advanced can…
Sponsor: UMC Utrecht • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
New MRI-Guided radiation aims to cut side effects in endometrial cancer
Symptom relief Recruiting nowThis study tests a new way to deliver radiation therapy for endometrial cancer using daily MRI scans to guide the beam. The goal is to give a higher dose of radiation to the tumor while sparing nearby organs like the bowel and bladder. Thirty participants will receive 15 sessions…
Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
Weighted blankets may ease anxiety for cancer patients during IV therapy
Symptom relief Recruiting nowThis study looks at whether using a weighted blanket during intravenous cancer treatment can help lower anxiety, stress, and depression, and improve comfort. About 152 adults with solid cancers who are starting their first IV therapy will be randomly assigned to receive either a …
Sponsor: Sultan Qaboos Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Could a nurse-led online therapy beat severe fatigue in advanced cancer?
Symptom relief Recruiting nowThis trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Fish oil and band workouts: a new hope against cancer muscle loss?
Symptom relief Recruiting nowThis study tests whether taking omega-3 fish oil capsules and doing simple resistance exercises with elastic bands can help cancer patients maintain muscle mass and strength. It involves 288 adults with various cancers who are at risk of muscle wasting. The goal is to improve phy…
Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
New writing therapy aims to ease fear in advanced cancer patients
Symptom relief Recruiting nowThis study tests a new program called EASE, which uses a simple writing exercise to help adults with advanced cancer manage their fear of the future and related trauma symptoms. The study will include 250 people with advanced solid tumors, glioblastoma, or certain ovarian or lung…
Sponsor: University of Colorado, Boulder • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
New trial uses DNA tests to match cancer patients to targeted drug cocktails
Knowledge-focused Recruiting nowThis large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 21, 2026 17:00 UTC
-
Ovarian Cancer's spread: scientists probe abdominal fluid for clues
Knowledge-focused Recruiting nowResearchers at the University of New Mexico collect ascites fluid, the liquid that builds up in the abdomen, from women undergoing surgery for ovarian cancer. They study this fluid and tumor tissue in the lab to learn how the tumor environment helps cancer spread within the perit…
Sponsor: New Mexico Cancer Research Alliance • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New study checks cancer Drug's effect on common medications
Knowledge-focused Recruiting nowThis study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Gene therapy survivors monitored for years in massive safety study
Knowledge-focused Recruiting nowThis study follows over 1,500 children and adults who previously received gene-modified T cell therapy for cancer. Researchers will track side effects, how long the modified cells last, and overall survival for up to 15 years. No new treatment is given—the goal is to understand l…
Phase 2/3 • Sponsor: Celgene • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Cancer care at home: what do patients and doctors really think?
Knowledge-focused Recruiting nowThis study interviews cancer care providers, patients, and caregivers to learn their thoughts and feelings about receiving hospital-level care at home. The goal is to understand what people know and believe about home hospital care, so that future programs can be designed to bett…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New study checks how liver issues affect cancer drug pelabresib
Knowledge-focused Recruiting nowThis early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New biobank aims to unlock secrets of Immunotherapy's harsh side effects
Knowledge-focused Recruiting nowThis study collects blood, tissue, and medical information from 240 cancer patients who have had serious side effects from immunotherapy. The goal is to store these samples in a national biorepository for future research. By studying these samples, scientists hope to better predi…
Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Cancer tissue bank opens to fuel research
Knowledge-focused Recruiting nowThis study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
What do women know about endometrial cancer? new study aims to find out
Knowledge-focused Recruiting nowThis study talks to women with and without endometrial cancer to learn what they know about risk factors and prevention options. Researchers hope to create a tool that helps women make informed decisions. About 45 women will take part at MD Anderson Cancer Center.
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
AI aims to speed up cancer trial enrollment for 70,000 patients
Knowledge-focused Recruiting nowThis study is building an AI tool called ACTIVATE that scans electronic health records to find cancer patients who may be eligible for clinical trials. Researchers will test whether sending alerts to doctors increases the number of patients starting trials. The goal is to make it…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Radiation aftermath: 700 cancer patients tracked for decades
Knowledge-focused Recruiting nowThis study follows about 700 cancer patients who have already received radiation therapy to understand the long-term side effects and how their disease progresses over time. No new treatments are given—researchers simply collect data from routine follow-up visits. The goal is to …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can science predict cancer fatigue? new study seeks answers
Knowledge-focused Recruiting nowThis study tracks 125 cancer patients receiving standard chemotherapy and radiation to understand why they feel tired. Researchers will collect blood, stool, and survey data before, during, and after treatment. The goal is to find patterns that could help predict and manage fatig…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New study aims to determine if less surgery is better for Early-Stage endometrial cancer
Knowledge-focused Recruiting nowThis study looks at whether removing only a few key lymph nodes (sentinel node biopsy) is better than removing no nodes at all in women with early-stage endometrial cancer. The goal is to see if this approach helps women return to normal activities faster and does not increase th…
Phase 3 • Sponsor: Queensland Centre for Gynaecological Cancer • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New program aims to boost clinical trial awareness among minorities
Knowledge-focused Recruiting nowThis study is testing an educational program designed to help racial and ethnic minority cancer patients make informed decisions about joining clinical trials. The program involves watching short videos and talking with a patient navigator. Researchers will measure changes in pat…
Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New tool aims to bridge the gap in cancer conversations
Knowledge-focused Recruiting nowThis study tests a communication tool called TrialTalk™ in cancer clinics. The goal is to see if it helps doctors and patients talk more clearly about treatment options. About 30 patients and their doctors will fill out questionnaires before and after a regular visit. The study f…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Ovarian cancer test accuracy under review in 1,000 women
Knowledge-focused Recruiting nowThis study looks at how well different labs agree when testing for a protein called FRa in stored tumor samples from women with ovarian cancer. About 1,000 women's archived tissue will be tested, but no new treatments or visits are needed. The goal is to improve consistency of FR…
Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
New registry aims to unlock secrets of rare cervical cancer
Knowledge-focused Recruiting nowThis study is creating a registry of 750 people with a rare and aggressive form of cervical cancer called neuroendocrine carcinoma. Researchers will collect information from medical records to learn more about the disease, how it is treated, and what happens to patients over time…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Could saving a tiny artery prevent deadly leaks after colon surgery?
Knowledge-focused Recruiting nowThis study looks at whether preserving the left colic artery during colon or rectal cancer surgery helps keep the remaining colon well-supplied with blood. Surgeons will temporarily clamp the main artery and use a green dye to measure blood flow. The goal is to see if this techni…
Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Can remote training bring better cancer care to underserved communities?
Knowledge-focused Recruiting nowThis study tests whether a telementoring program called ECHO can improve the quality of palliative care for advanced cancer patients in underserved areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia. Researchers will train local doctors through online clinics and w…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
New toolkit aims to fix cancer trial diversity gap
Knowledge-focused Recruiting nowThis study tests a program called SUPPORT that helps Black and Latino cancer patients learn about and join clinical trials. The program includes a website and a navigator who guides patients. Researchers will see if this increases the number of patients referred to and enrolled i…
Sponsor: Eastern Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Can special heart checkups protect cancer patients from their own treatment?
Knowledge-focused Recruiting nowSome cancer drugs cause rare but serious heart and metabolic problems. This study follows 5,000 cancer patients across several French hospitals who receive a dedicated heart checkup and ongoing follow-up through cardio-oncology programs. Researchers track how many patients benefi…
Sponsor: Groupe Hospitalier Pitie-Salpetriere • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Blood test may personalize ovarian cancer care after surgery
Knowledge-focused Recruiting nowThis study is testing whether a blood test that looks for tiny bits of tumor DNA (called ctDNA) can help doctors decide who needs extra treatment after ovarian cancer surgery. Researchers will analyze stored blood samples from 50 patients taken before and after surgery. The goal …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
EU-Wide survey aims to uncover hidden gaps in mental health support for cancer patients
Knowledge-focused Recruiting nowThis study uses online surveys to explore whether cancer patients and their family members across the European Union have equal access to mental health screening and psychological support. Researchers will analyze responses from 2,000 participants to identify disparities, barrier…
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Could a simple dye replace major surgery for ovarian cancer staging?
Knowledge-focused Recruiting nowThis study looks at whether a blue dye injected into the ovary can help doctors find the first lymph node where cancer might spread, instead of removing many lymph nodes. The goal is to see if this less invasive method works as well as standard surgery for early-stage ovarian can…
Sponsor: Faculty of Medicine of Tunis • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
What do you risk for a chance at remission? cell therapy survey asks
Knowledge-focused Recruiting nowCell therapies such as CAR-T and TIL therapy are emerging options for advanced solid tumors, but their benefits are uncertain and side effects can be severe. Researchers at Zhejiang University are surveying about 420 cancer doctors and 600 patients in China to learn how each grou…
Sponsor: Zhejiang University • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Chemo ear damage worse for poorer patients, study warns
Knowledge-focused Recruiting nowThis study looks at how platinum-based chemotherapy can cause permanent hearing loss in cancer patients, and whether people from poorer backgrounds are more affected. Researchers will test hearing and thinking skills in 172 patients from North West England before and after treatm…
Sponsor: Lancaster University • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Cancer diagnosis can shock the whole family: study maps who struggles most
Knowledge-focused Recruiting nowResearchers at Lille University are following 350 people, including cancer patients recently diagnosed with breast, gynecological, testicular or digestive cancer, their caregivers, and healthcare professionals. Over one year, participants answer questionnaires about post-traumati…
Sponsor: Lille University • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Scientists gather tumor samples to unlock new cancer treatments
Knowledge-focused Recruiting nowThis study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Cancer data pooling study aims to connect the dots across trials
Knowledge-focused Recruiting nowThis study enrolls adults with cancer or benign tumors who are already participating in other trials at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a patient's past, current, and future studies. The goal is to …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Can protein patterns in stored tumors point to new treatment targets?
Knowledge-focused Recruiting nowThis observational study in Vietnam looks at archived tumor samples from patients with several solid cancers, including liver, colorectal, gastric, breast, lung, endometrial, melanoma, and pancreatic cancer. Researchers will measure the presence of two proteins, ENPP1/cGAS and FA…
Sponsor: Tam Anh Research Institute • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Do men and women react differently to immunotherapy? new study aims to find out
Knowledge-focused Recruiting nowThis study looks at whether men and women experience different side effects from cancer immunotherapy. Researchers will track symptoms and quality of life in 100 adults starting standard immunotherapy. The goal is to better understand how sex and gender influence treatment experi…
Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
500 women with advanced uterine cancer to have tumors genetically profiled
Knowledge-focused Recruiting nowThis study looks at the genetic makeup of advanced endometrial cancer in 500 women in Russia. Researchers will test tumor samples for specific gene changes to see how common they are and what treatments patients receive. The goal is to gather information, not to test a new treatm…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
New study aims to reduce bleeding and clotting risks in cancer surgery patients on blood thinners
Knowledge-focused Recruiting nowThis study follows 700 cancer patients who take blood thinners and are scheduled for surgery or medical procedures. Researchers will track how often major bleeding or clotting events occur within 30 days after the procedure. The goal is to see if current blood thinner management …
Sponsor: Ottawa Hospital Research Institute • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Blood biomarkers may predict cancer treatment side effects
Knowledge-focused Recruiting nowThis pilot study investigates whether certain molecules in the blood, called miRNAs and proteins, change during cancer treatment and whether these changes can signal early signs of heart or lung damage. Researchers will compare blood samples from patients receiving radiation or c…
Sponsor: University Hospitals Coventry and Warwickshire NHS Trust • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
New study gathers key materials to create personalized cell therapies for tough cancers
Knowledge-focused Recruiting nowThis observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Brazilian study maps HER2 in Women's cancers to guide future treatments
Knowledge-focused Recruiting nowThis study will test tumor samples from 350 adults with gynecological cancers (endometrial, ovarian, cervical, vulvar, and vaginal) to see how often they have high levels of the HER2 protein. Researchers will use two standard lab tests to measure HER2. The goal is to learn how co…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
At-Home swab could spot uterine cancer in lynch syndrome patients
Knowledge-focused Recruiting nowThis study explores whether people with Lynch syndrome can use a self-collected vaginal swab at home to detect early signs of uterine cancer. Researchers will enroll 30 participants who will collect samples and answer surveys. The main goal is to see if this approach is practical…
Sponsor: University of British Columbia • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Can discarded ovarian tissue reveal how childhood conditions shape future fertility?
Knowledge-focused Recruiting nowThis study collects discarded ovarian tissue from girls aged 0 to 18 who are having surgery on their ovary for conditions like cysts or torsion. Researchers will examine the tissue to count follicles at different stages and compare them across ages and conditions. The goal is to …
Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Money for travel and childcare may open cancer trials to more people
Knowledge-focused Recruiting nowThis study looks at whether offering money for things like travel, lodging, and childcare helps more people from different backgrounds join cancer clinical trials. Researchers will track enrollment and retention of 1,200 patients who are already in a cancer trial. They will compa…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Brazil launches major study to map ovarian cancer treatment gaps
Knowledge-focused Recruiting nowThis observational study will look at how ovarian cancer is currently treated in Brazil, including surgeries, chemotherapy, and genetic testing. Researchers will collect data from 250 patients to find what is working well and what needs improvement. The goal is to use these insig…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Scientists hunt for hidden cancer clues in families
Knowledge-focused Recruiting nowThis study aims to learn how genes and the environment contribute to rare tumors and cancer risk in individuals and families. Researchers will collect medical histories, genetic samples, and health data from up to 500 participants of all ages. No treatment is given; the goal is t…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Chatbot vs. standard care: which boosts genetic testing in young cancer patients?
Knowledge-focused Recruiting nowThis study tests whether a digital chatbot can help more adolescents and young adults (AYA) with cancer get genetic counseling and testing compared to standard remote services. About 535 participants aged 18-39 will use either a chatbot or standard telehealth. The goal is to see …
Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
AI-Guided radiation may shield ovaries in young cancer patients
Knowledge-focused Recruiting nowThis study tests whether a new type of adaptive radiotherapy can reduce radiation exposure to the ovaries in young women (ages 18-50) receiving pelvic radiation for cancers like uterine, rectal, or cervical cancer. Using advanced imaging and an AI treatment planning system, resea…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Tracking infection markers over time may spot sepsis sooner in cancer patients
Knowledge-focused Recruiting nowThis study tests whether tracking changes in infection markers and blood culture results over time can help detect sepsis earlier and monitor treatment in adults with cancer. Researchers will follow 100 patients with suspected sepsis during their hospital stay and for up to 30 da…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Can a simple screening help cancer patients get mental health support?
Knowledge-focused Recruiting nowThis study tests a program that screens cancer patients for emotional distress and refers them to mental health services if needed. It involves 50 English- or Spanish-speaking adults with new solid tumor cancers at Jamaica Hospital Medical Center. The goal is to see if such a pro…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
New imaging registry aims to sharpen cancer treatment precision
Knowledge-focused Recruiting nowThis study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …
Sponsor: Mark C Burgmans, MD PhD • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Could a workout after cancer treatment help you live longer?
Knowledge-focused Recruiting nowThis study looks at whether exercise after finishing cancer treatment is linked to better outcomes, like longer survival without the cancer coming back. Researchers will analyze data from 1,000 adult cancer survivors at Memorial Sloan Kettering. The goal is to see if those who ex…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Researchers launch major tissue bank to unlock secrets of mesothelioma
Knowledge-focused Recruiting nowThis study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Cancer samples sought to unlock treatment secrets
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
No treatment, just samples: new study aims to understand cancer immunity
Knowledge-focused Recruiting nowThis study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Study explores how medical info delivery shapes cancer care decisions
Knowledge-focused Recruiting nowThis study looks at how the way medical information is presented influences treatment choices for people with advanced cancer. About 400 participants will fill out questionnaires and review made-up case scenarios. The goal is to learn how to better communicate health options to e…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Cancer genetics study aims to personalize treatment
Knowledge-focused Recruiting nowThis study collects blood or cheek swab samples from 1,100 cancer patients at the National Cancer Institute to analyze genetic differences that may influence how their bodies process cancer treatments. The goal is to understand why some patients experience more side effects or le…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Yale launches massive blood repository to unlock cancer secrets
Knowledge-focused Recruiting nowThis study collects blood samples from people with cancer or at high risk for cancer to create a large, well-organized repository for research. The goal is to provide scientists with a valuable resource to study cancer through liquid biopsies, which may lead to better detection a…
Sponsor: Yale University • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
Can 3D-Printed molds pinpoint cancer hotspots?
Knowledge-focused Recruiting nowThis trial tests whether 3D-printed molds, created from radiological images, can guide pathologists to sample the most informative parts of a removed tumor. Currently, sampling is done by eye, which may miss key regions. The study will compare samples taken with the mold to stand…
Sponsor: Tampere University Hospital • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
Can we predict dangerous side effects when combining radiation and immunotherapy?
Knowledge-focused Recruiting nowThis study is a large registry that tracks cancer patients who receive both radiotherapy and molecular therapies, such as immunotherapy. The goal is to better understand how these two treatments interact and to identify how often severe side effects occur. By collecting data from…
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Tumor DNA mapping may unlock personalized cancer therapies
Knowledge-focused Recruiting nowThis study explores whether analyzing the genetic makeup of a tumor biopsy can help identify advanced cancer patients who might benefit from targeted treatments. Adults with solid tumors who have no standard treatment options will have a biopsy of their lesion for molecular profi…
Sponsor: Ulrik Lassen • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
AI platform aims to unlock Real-World cancer data on a massive scale
Knowledge-focused Recruiting nowThis study enrolls people diagnosed with cancer to build a large registry using Olivia, an AI-powered health platform. The platform will collect and combine electronic health records and patient-reported outcomes from over 1,000 healthcare systems. The goal is to create a compreh…
Sponsor: Tempus AI • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
New study aims to bridge psychosocial care gap for cancer survivors
Knowledge-focused Recruiting nowThis study tests whether a routine digital screening followed by a supportive phone call can help cancer survivors get the emotional and social support they need after finishing primary treatment. Fifty adults who have completed cancer therapy will take part. The goal is to see i…
Sponsor: University Hospital, Basel, Switzerland • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Could vitamin d predict cervical cancer treatment success?
Knowledge-focused Recruiting nowThis study looks at whether vitamin D levels in the blood and cervical fluid before treatment can predict how well chemoradiotherapy works for locally advanced cervical cancer. Researchers will measure vitamin D in 100 women undergoing standard treatment and track their response …
Sponsor: University of Kragujevac • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Can modern Radiotherapy's late effects be predicted?
Knowledge-focused Recruiting nowThis study follows a large group of children and young adults who received radiation therapy for cancer, to see how their health and quality of life evolve over many years. By collecting medical data and blood samples in a European registry, researchers aim to identify late effec…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Reading Cancer's genetic playbook: a quest to match patients to the right experimental therapy
Knowledge-focused Recruiting nowThis observational study aims to identify genetic mutations in adults with advanced solid cancers who are being considered for or are already in early-phase clinical trials. By analyzing tumor and blood samples over time, researchers hope to understand how these mutations influen…
Sponsor: Institute of Cancer Research, United Kingdom • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Can AI outthink cancer experts? a landmark trial pits five AIs against tumor boards
Knowledge-focused Recruiting nowThis trial asks whether five advanced AI models can match the treatment recommendations of expert tumor boards for cancer patients. Using 100 standardized synthetic cases across breast, lung, urological, digestive, and gynecological cancers, each AI and two independent tumor boar…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Can chemo and radiation steal fertility? a massive study aims to find out
Knowledge-focused Recruiting nowThis observational study tracks 7,000 men and women with cancer to see how treatments like chemotherapy, radiation, and immunotherapy affect fertility. In women, researchers measure a hormone called AMH to gauge ovarian reserve; in men, they analyze sperm quality. The goal is to …
Sponsor: Michael von Wolff • Aim: Knowledge-focused
Last updated Aug 01, 2026 00:00 UTC
-
Could centralized surgery boost ovarian cancer survival?
Knowledge-focused Recruiting nowThis study examines whether concentrating ovarian cancer surgery in specialized centers and changes in treatment during the COVID-19 pandemic affect how long patients live without their cancer returning. Researchers will follow about 200 women diagnosed with epithelial ovarian ca…
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Scientists probe hidden clues to immunotherapy success in endometrial cancer
Knowledge-focused Recruiting nowThis study investigates why some advanced or recurrent endometrial cancers respond to immunotherapy while others do not. Researchers will collect tumor samples from 510 patients before they start immunotherapy and use lab-grown tumor models to study molecular and genetic features…
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Bacteria in the mouth and gut may predict who responds to cancer immunotherapy
Knowledge-focused Recruiting nowThis study looks at the bacteria living in the mouth, stool, and tumors of Colombian adults with advanced cancers of the stomach, colon, breast, cervix, or head and neck who are starting immunotherapy as standard care. Researchers will compare these microbial profiles to those of…
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
New robot arm takes on cancer surgery – first safety check begins
Knowledge-focused Recruiting nowThis study will test a new robotic surgery platform called RonovoTM in 40 adults with cancer who need elective surgery. The robot helps surgeons perform minimally invasive procedures in digestive, thoracic, urology, and gynecology areas. Researchers will track complications, tech…
Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
New approach aims to make repeat radiation safer for cancer patients
Knowledge-focused Recruiting nowThis study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…
Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can a simple blood test predict leukemia risk after cancer therapy?
Knowledge-focused Recruiting nowThis study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Blood test may guide cancer care without biopsy
Knowledge-focused Recruiting nowThis study explores whether a blood test that detects circulating tumor DNA (ctDNA) can help doctors personalize treatment for people with five types of advanced cancer: non-small cell lung cancer, gastrointestinal stromal tumors, colorectal cancer, biliary tract cancer, and ovar…
Sponsor: Royal Marsden NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Cancer Patients' supplement use under the microscope
Knowledge-focused Recruiting nowThis observational study will survey 1,000 cancer patients about their use of dietary supplements like vitamins, minerals, and herbal products. Researchers want to know how common supplement use is, whether patients experience side effects, and if these supplements could interact…
Sponsor: Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI) • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New italian tool aims to ease MRI anxiety for cancer patients
Knowledge-focused Recruiting nowThis study is translating and testing an Italian version of a questionnaire that measures anxiety in cancer patients during whole-body MRI scans. Researchers will enroll 175 adult cancer patients at the European Institute of Oncology. The goal is to ensure the Italian version is …
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New PET imaging study aims to sharpen tumor detection
Knowledge-focused Recruiting nowThis study is collecting data from 2,000 adults with solid tumors who undergo theranostic PET scans as part of their routine care. The goal is to see how well these scans detect tumors and match with lab results, which could help doctors make better treatment decisions. Participa…
Sponsor: University Hospital, Essen • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New registry aims to learn from Real-World retreatment of gynecologic cancers
Knowledge-focused Recruiting nowThis observational registry is gathering data from 500 adults whose gynecologic cancer has returned after prior radiation therapy. Doctors are using reirradiation or other ablative strategies as part of standard care, and the registry will track how well these treatments control …
Sponsor: Affidea Nu-med Center of Oncological DIagnostics and Therapy • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Protein clues may predict cervical cancer return
Knowledge-focused Recruiting nowThis study is looking at 180 women with advanced cervical cancer who were treated with radiation and chemotherapy. Researchers want to see if high levels of certain proteins (called IAPs) in the original tumor biopsy can predict whether the cancer will come back within two years.…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study aims to uncover why some women have worse sexual side effects from radiation
Knowledge-focused Recruiting nowThis study is observing 300 women with female sexual organs who are receiving radiotherapy for certain cancers. Researchers want to understand why some patients have more sexual side effects than others. They will track sexual quality of life and look at radiation doses to find p…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Gene-Guided cancer therapy: a new hope for advanced tumors?
Knowledge-focused Recruiting nowThis study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…
Sponsor: Seoul National University Bundang Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Decoding Immunotherapy's liver side effect to keep cancer treatment on track
Knowledge-focused Recruiting nowThis study looks at liver inflammation (hepatitis) that can occur in cancer patients treated with immune checkpoint inhibitors, a type of immunotherapy. Researchers aim to describe the different patterns of liver injury and how they respond to treatment. By collecting real-world …
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study aims to unravel cancer blood clot mysteries
Knowledge-focused Recruiting nowThis study is collecting blood and urine samples from 150 cancer patients who have had blood clots. The goal is to learn more about why clots happen in cancer and how to prevent them. Participants will be followed over time to track clot recurrence and bleeding risks.
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood test aims to spot hidden cancer cells in 9 tumor types
Knowledge-focused Recruiting nowThis study is looking for certain cells in the blood of people with 9 types of advanced cancers that have spread. Researchers will take one blood sample from each of 450 participants before they start a new treatment. They will use two different lab methods to see if they can fin…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists probe immune resistance in tumors to outsmart cancer
Knowledge-focused Recruiting nowThis study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
500 cancer patients join quest to unlock precision medicine secrets
Knowledge-focused Recruiting nowThis study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Blood biopsy study aims to improve cancer detection and monitoring
Knowledge-focused Recruiting nowThis study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
10,000 cancer patients join ontario Gene-Mapping effort to personalize care
Knowledge-focused Recruiting nowThis study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer) to create a province-wide gene database. The goal is to help doctors identify which targeted drugs or clinical trials might work best for each …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC